<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id><journal-title-group><journal-title>Frontiers in Endocrinology</journal-title></journal-title-group><issn pub-type="epub">1664-2392</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6291425</article-id><article-id pub-id-type="doi">10.3389/fendo.2018.00748</article-id><article-categories><subj-group subj-group-type="heading"><subject>Endocrinology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Sirtuins and Insulin Resistance </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Shuang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/650123/overview"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Xiaoqiang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/120979/overview"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hou-Zao</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/54892/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Internal Medicine, Peking Union Medical College Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><text><SENT sid="1" pm="."><plain>Edited by: Yang Yang, Northwest University, China </plain></SENT>
</text></p></fn><fn fn-type="edited-by"><p><text><SENT sid="2" pm="."><plain>Reviewed by: Pieter de Lange, Università degli Studi della Campania “Luigi Vanvitelli” Caserta, Italy; Rosalba Senese, Università degli Studi della Campania “Luigi Vanvitelli” Caserta, Italy; Maria Moreno, University of Sannio, Italy; Stuart Maudsley, University of Antwerp, Belgium </plain></SENT>
</text></p></fn><corresp id="c001">*Correspondence: Xiaoqiang Tang <email>tangxiaoqiang@scu.edu.cn</email></corresp><corresp id="c002">Hou-Zao Chen <email>chenhouzao@ibms.cams.cn</email>; <email>houzao@gmail.com</email></corresp><fn fn-type="other" id="fn001"><p><text><SENT sid="3" pm="."><plain>This article was submitted to Cellular Endocrinology, a section of the journal Frontiers in Endocrinology </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>748</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Zhou, Tang and Chen.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Zhou, Tang and Chen</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>The mammalian Sirtuins (SIRT1-7) are an evolutionarily conserved family of NAD+-dependent deacylase and mono-ADP-ribosyltransferase. </plain></SENT>
<SENT sid="5" pm="."><plain>Sirtuins display distinct subcellular localizations and functions and are involved in cell survival, senescence, metabolism and genome stability. </plain></SENT>
<SENT sid="6" pm="."><plain>Among the mammalian Sirtuins, SIRT1 and SIRT6 have been thoroughly investigated and have prominent metabolic regulatory roles. </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, SIRT1 and SIRT6 have been implicated in obesity, insulin resistance, type 2 diabetes mellitus (T2DM), fatty liver disease and cardiovascular diseases. </plain></SENT>
<SENT sid="8" pm="."><plain>However, the roles of other Sirtuins are not fully understood. </plain></SENT>
<SENT sid="9" pm="."><plain>Recent studies have shown that these Sirtuins also play important roles in inflammation, mitochondrial dysfunction, and energy metabolism. </plain></SENT>
<SENT sid="10" pm="."><plain>Insulin resistance is the critical pathological trait of obesity and metabolic syndrome as well as the core defect in T2DM. </plain></SENT>
<SENT sid="11" pm="."><plain>Accumulating clinical and experimental animal evidence suggests the potential roles of the remaining Sirtuins in the regulation of insulin resistance through diverse biological mechanisms. </plain></SENT>
<SENT sid="12" pm="."><plain>In this review, we summarize recent advances in the understanding of the functions of Sirtuins in various insulin resistance-associated physiological processes, including inflammation, mitochondrial dysfunction, the insulin signaling pathway, glucose, and lipid metabolism. </plain></SENT>
<SENT sid="13" pm="."><plain>In addition, we highlight the important gaps that must be addressed in this field. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>sirtuins</kwd><kwd>insulin resistance</kwd><kwd>senescaging</kwd><kwd>inflammation</kwd><kwd>mitochondrial dysfunction</kwd></kwd-group></SecTag><counts><fig-count count="3"/><table-count count="0"/><equation-count count="0"/><ref-count count="291"/><page-count count="21"/><word-count count="19317"/></counts></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s1"><title><text><SENT sid="14" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="15" pm="."><plain>The increasing prevalence of obesity and associated metabolic syndrome (including type 2 diabetes mellitus [T2DM], nonalcoholic fatty liver disease [NAFLD], atherosclerosis and atherosclerotic heart disease) is an increasingly severe challenge in public health (1). </plain></SENT>
<SENT sid="16" pm="."><plain>Insulin resistance is the critical, universal pathological feature of these diseases, especially T2DM. </plain></SENT>
<SENT sid="17" pm="."><plain>Insulin is a major hormone secreted by pancreatic β cells after nutrient stimulation and plays a critical role in reducing blood glucose concentration by facilitating glucose uptake by skeletal muscle and adipose tissue and inhibiting endogenous glucose production in the liver (2–4). </plain></SENT>
<SENT sid="18" pm="."><plain>Insulin resistance occurs when cells are incapable of efficiently responding to a normal dose of insulin (2–4). </plain></SENT>
<SENT sid="19" pm="."><plain>The development of insulin resistance is a multistep, complex process influenced by genetics and environments (3). </plain></SENT>
<SENT sid="20" pm="."><plain>Although the precise pathogenesis of insulin resistance remains incompletely understood, several mechanisms are proposed to be involved, including defects in the insulin signaling pathway, ectopic lipid accumulation, systemic inflammation, mitochondrial dysfunction, oxidative stress, and endoplasmic reticulum (ER) stress, as reviewed elsewhere (1, 5, 6). </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>The mammalian Sirtuins are a family of NAD+-dependent deacetylases (7). </plain></SENT>
<SENT sid="22" pm="."><plain>This family consists of seven members (SIRT1-SIRT7), which share the conserved Sirtuin domain conferring NAD+-dependent deacetylase activity but have variable amino- and carboxy-terminal extensions and display distinct subcellular localization and biological functions (8, 9). </plain></SENT>
<SENT sid="23" pm="."><plain>SIRT1 is mainly localized to the nucleus (10), but it shuttles between the nucleus and cytoplasm during development and in response to physiological and pathological stress (11). </plain></SENT>
<SENT sid="24" pm="."><plain>In contrast to SIRT1, mammalian SIRT2 is mainly localized to the cytoplasm (10, 12) but is also found in the nucleus (13). </plain></SENT>
<SENT sid="25" pm="."><plain>SIRT3, SIRT4, and SIRT5 are localized to mitochondria (10, 14), whereas SIRT6 and SIRT7 are found in the nucleus (10). </plain></SENT>
<SENT sid="26" pm="."><plain>SIRT6 is a chromatin-associated protein, and SIRT7 resides in the nucleolus (15, 16). </plain></SENT>
<SENT sid="27" pm="."><plain>Deacetylase activity was initially reported as conserved in mammalian Sirtuins, but different Sirtuins exhibit different acyl group preferences (17). </plain></SENT>
<SENT sid="28" pm="."><plain>Among the seven Sirtuins, SIRT4-7 exhibit weak or undetectable deacetylation activity in vitro (10, 18). </plain></SENT>
<SENT sid="29" pm="."><plain>SIRT2 reportedly possesses efficient demyristoylase activity (18). </plain></SENT>
<SENT sid="30" pm="."><plain>SIRT5 is reportedly an efficient NAD+-dependent protein, lysine desuccinylase and demalonylase (19), while SIRT4 and SIRT6 reportedly possess ADP-ribosyltransferase activity (20, 21). </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>Mammalian Sirtuins regulate a wide variety of cellular processes, including metabolism, mitochondrial homeostasis, oxidative stress, inflammation, autophagy and apoptosis (22). </plain></SENT>
<SENT sid="32" pm="."><plain>Sirtuins also play important roles in aging and aging-related diseases, such as obesity, T2DM, cardiovascular disease, cancer, neurodegenerative diseases (23). </plain></SENT>
<SENT sid="33" pm="."><plain>SIRT1 and SIRT6 are the most extensively characterized Sirtuins. </plain></SENT>
<SENT sid="34" pm="."><plain>A large body of literature indicates that these two Sirtuins play an important role in metabolism, and they have also recently attracted increased attention with regard to their protective roles in maintaining insulin sensitivity, as reviewed elsewhere (24–26). </plain></SENT>
<SENT sid="35" pm="."><plain>Compared to the metabolic roles of SIRT1 and SIRT6, the metabolic roles of other Sirtuins remain poorly understood. </plain></SENT>
<SENT sid="36" pm="."><plain>Here, we review the recent advances in the understanding of the roles of Sirtuins in inflammation, mitochondrial dysfunction, and oxidative stress and discuss their possible roles in insulin resistance. </plain></SENT>
</text></p></sec></SecTag><sec id="s2"><title><text><SENT sid="37" pm="."><plain>Sirtuins in Inflammation </plain></SENT>
</text></title><p><text><SENT sid="38" pm="."><plain>Obesity-induced chronic, low-grade inflammation is one of the most important contributors to the pathogenesis of insulin resistance (27–29). </plain></SENT>
<SENT sid="39" pm="."><plain>Adipose tissue is not only an insulin-targeting organ for lipid metabolism but also an endocrine organ that secretes hormones, cytokines, and chemokines to influence insulin sensitivity. </plain></SENT>
<SENT sid="40" pm="."><plain>For instance, adipocytes secrete adipokines, such as leptin and adiponectin, to promote insulin sensitivity (30, 31), and resistin and retinol-binding protein 4 (RBP4) to impair insulin sensitivity (32, 33). </plain></SENT>
<SENT sid="41" pm="."><plain>Importantly, adipose tissue is a critical initiator of the inflammatory response to obesity (28). </plain></SENT>
<SENT sid="42" pm="."><plain>In obesity, metabolism and gene expression of adipocytes change, resulting in increased lipolysis of adipocytes, the release of free fatty acids and proinflammatory cytokines and activation of M1 macrophages (27–29). </plain></SENT>
<SENT sid="43" pm="."><plain>M1 macrophages produce a large number of proinflammatory mediators, such as TNF-α, IL-1β, and resistin, that act on adipocytes to induce an insulin-resistant state and activate inflammatory pathways in insulin-targeting cells. </plain></SENT>
<SENT sid="44" pm="."><plain>Ultimately, ectopic lipid deposition and increased expression of inflammatory mediators in the liver and skeletal muscle lead to impaired insulin signaling and exacerbate systemic insulin resistance (29). </plain></SENT>
<SENT sid="45" pm="."><plain>Signals from all the proinflammatory mediators converge on inflammatory signaling pathways, including jun-n-terminal kinase (JNK) and inhibitor of nuclear factor κB (NF-κB) kinase (IKK) (27, 34, 35). </plain></SENT>
<SENT sid="46" pm="."><plain>Inhibition of insulin receptor downstream signaling is the primary mechanism for inflammation-induced insulin resistance (27). </plain></SENT>
<SENT sid="47" pm="."><plain>Activated JNK or IKK can phosphorylate the insulin receptor (IR) and insulin receptor substrate (IRS) proteins and decrease their tyrosine phosphorylation, thus leading to decreased activation of PI3-kinase and Akt and resistance to the metabolic actions of insulin (34, 36). </plain></SENT>
<SENT sid="48" pm="."><plain>In addition, activation of the JNK and IKK pathways can induce the production of inflammatory mediators, while the Sirtuin family plays essential roles in inflammation, which comprehensively contributes to insulin resistance. </plain></SENT>
</text></p><sec><title><text><SENT sid="49" pm="."><plain>Inflammatory Transcriptional Factor </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>NF-κB is a key transcriptional factor that mediates the expression of multiple inflammatory factors, including TNF-α, IL-1β, and IL-6. </plain></SENT>
<SENT sid="51" pm="."><plain>The acetylation of NF-κB promotes its nuclear translocation and activation. </plain></SENT>
<SENT sid="52" pm="."><plain>SIRT1 has been demonstrated to repress inflammation in multiple tissues and cells (37–40). </plain></SENT>
<SENT sid="53" pm="."><plain>In particular, SIRT1 suppresses inflammation in both adipocytes (39, 41) and macrophages (42), which leads to a reduction of adipose tissue inflammation. </plain></SENT>
<SENT sid="54" pm="."><plain>SIRT1 deacetylates p65 subunit of NF-κB at lysine 310 (K310) and inhibits the transcriptional activity of NF-κB (43). </plain></SENT>
<SENT sid="55" pm="."><plain>Moreover, SIRT1 interacts with transducing-like enhancer of split 1 (TLE1), a co-repressor of NF-κB, to inhibit NF-κB-mediated transcription (44). </plain></SENT>
<SENT sid="56" pm="."><plain>In addition, SIRT1 deacetylates activator protein-1 (AP-1) to reduce the expression of COX-2 in macrophages and deacetylates p53 to repress macrophage activation (45, 46). </plain></SENT>
<SENT sid="57" pm="."><plain>Similar to SIRT1, SIRT2 also binds to NF-κB and mediates the deacetylation of NF-κB subunit p65 at K310, which leads to the inhibition of the expression of NF-κB target inflammatory genes in fibroblasts, macrophages and microglial cells (47–49). </plain></SENT>
<SENT sid="58" pm="."><plain>SIRT2-mediated inhibition of NF-κB and inflammation contributes to its anti-inflammatory function in an experimental colitis mouse model (49), neuroinflammation (48, 50, 51), collagen-induced arthritis (52), and microvascular inflammation in ob/ob septic mice (53). </plain></SENT>
<SENT sid="59" pm="."><plain>In addition to SIRT2, SIRT4 can regulate the activation of NF-κB. </plain></SENT>
<SENT sid="60" pm="."><plain>SIRT4 has been shown to negatively regulate cigarette smoke extract (CSE)-induced NF-κB activation by inhibiting the degradation of IκBα and inhibiting NF-κB target gene expression, including the proinflammatory cytokines IL-1β, TNF-α, and IL-6, resulting in inhibition of CSE-induced mononuclear cell adhesion to human pulmonary microvascular endothelial cells (54). </plain></SENT>
<SENT sid="61" pm="."><plain>SIRT4 can prevent NF-κB nuclear translocation as well as the transcriptional activity of NF-κB, thereby suppressing inflammation in human umbilical vein endothelial cells (55). </plain></SENT>
<SENT sid="62" pm="."><plain>Interestingly, the role of SIRT5 in inflammation is controversial. </plain></SENT>
<SENT sid="63" pm="."><plain>Recently, Qin and colleagues showed that SIRT5 deficiency decreased toll-like receptor (TLR)-triggered inflammation in both acute and immunosuppressive phases of sepsis (56). </plain></SENT>
<SENT sid="64" pm="."><plain>Mechanistically, SIRT5 competes with SIRT2 to interact with NF-κB p65 in a deacetylase activity-independent manner and thus blocks the deacetylation of p65 by SIRT2, which consequently leads to the activation of the NF-κB pathway and induction of its downstream cytokines in macrophages (56). </plain></SENT>
<SENT sid="65" pm="."><plain>However, Wang and colleagues found that SIRT5 desuccinylates and actives pyruvate kinase isoform M2 (PKM2) by promoting its dimerization and nuclear accumulation, thereby decreasing proinflammatory cytokine IL-1β production in LPS-activated macrophages (57). </plain></SENT>
<SENT sid="66" pm="."><plain>As hyperproduction of IL-1β contributes to increased susceptibility to inflammatory bowel disease, Sirt5-deficient mice are more susceptible to dextran sulfate sodium (DSS)-induced colitis (57). </plain></SENT>
<SENT sid="67" pm="."><plain>Interestingly, Sirt6 deficient mice display increased expression of NF-κB-dependent genes in multiple tissues (58). Sirt6 deletion increases inflammation in the mice adipose tissue and promotes HFD-induced insulin resistance (59, 60). </plain></SENT>
<SENT sid="68" pm="."><plain>Mechanistically, SIRT6 binds to the NF-κB subunit RelA and deacetylates histone H3 lysine 9 (H3K9) at NF-κB target gene promoters, which leads to a reduction of NF-κB target gene expression (58). </plain></SENT>
<SENT sid="69" pm="."><plain>These findings suggest that the Sirtuins target inflammatory transcriptional factors (e.g., NF-κB and AP1) directly or indirectly to contribute to insulin resistance comprehensively. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="70" pm="."><plain>Inflammasome </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>The anti-inflammatory role of Sirtuins involves other mechanisms. </plain></SENT>
<SENT sid="72" pm="."><plain>The Nod-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome is a multiprotein complex that orchestrates the innate immune responses of macrophages by controlling the activation of caspase-1 and the release of the proinflammatory cytokines IL-1β and IL-18 (61–63). </plain></SENT>
<SENT sid="73" pm="."><plain>Obesity-related inflammation is partly mediated by the NLRP3 inflammasome, and NLRP3 activation exacerbates obesity-linked diseases (64, 65). </plain></SENT>
<SENT sid="74" pm="."><plain>Resveratrol, a SIRT1 activator, inhibits ionizing irradiation-induced inflammation in mesenchymal stem cells via suppressing NLRP3 inflammasome activation (66). </plain></SENT>
<SENT sid="75" pm="."><plain>In a murine model of sepsis, Sirt1 deletion results in increasing lung inflammasome activation and inflammatory lung injury (67). </plain></SENT>
<SENT sid="76" pm="."><plain>A recent study demonstrated that silybin prevents NLRP3 inflammasome activation during NAFLD through SIRT2 (68). </plain></SENT>
<SENT sid="77" pm="."><plain>However, further studies are needed to clarify the mechanism underlying SIRT2-mediated regulation of NLRP3 inflammasome activity. </plain></SENT>
<SENT sid="78" pm="."><plain>In a human fasting/refeeding study, Traba and colleagues observed that fasting leads to a reduction in NLRP3 inflammasome activation (69). </plain></SENT>
<SENT sid="79" pm="."><plain>SIRT3 deletion in a human macrophage line increases NLRP3 inflammasome activation, accompanied by excessive mitochondrial ROS production (69). </plain></SENT>
<SENT sid="80" pm="."><plain>Pharmacologic and genetic SIRT3 activation enhances mitochondrial function and suppresses NLRP3 activity in THP-1 monocyte cells and in leukocytes extracted from healthy volunteers and from refeeding individuals (69). </plain></SENT>
<SENT sid="81" pm="."><plain>The authors concluded that nutrient levels regulate the NLRP3 inflammasome partly through SIRT3-mediated mitochondrial homeostatic control. </plain></SENT>
<SENT sid="82" pm="."><plain>Similarly, Chen et al. reported that trimethylamine-N-oxide (TMAO) increases ROS production by inhibiting the SIRT3-SOD2-mitochondrial signaling pathway, which leads to NLRP3 inflammasome activation and consequently promotes vascular inflammation (70). </plain></SENT>
<SENT sid="83" pm="."><plain>Defective autophagy in monocytes or macrophages might result in NLRP3 inflammasome activation and cause vascular metabolic inflammation (71–73). </plain></SENT>
<SENT sid="84" pm="."><plain>Acetylation of ATG5, an autophagy-related protein, inhibits autophagosome maturation and induces NLRP3 inflammasome activation (74). </plain></SENT>
<SENT sid="85" pm="."><plain>Recently, Liu and colleagues demonstrated that SIRT3 binds with ATG5 and deacetylates it, while SIRT3-deficient macrophages display impaired autophagy, leading to accelerated NLRP3 inflammasome activation and endothelial dysfunction (73). </plain></SENT>
<SENT sid="86" pm="."><plain>These studies suggest that SIRT3 may inhibit NLRP3 inflammasome activation by regulating mitochondrial function, ROS production, and autophagy. </plain></SENT>
<SENT sid="87" pm="."><plain>As SIRT2 has also been shown to regulate NLRP3 inflammasome activation (68), the potential synergistic effect on regulation of NLRP3 inflammasome activation between SIRT3 and SIRT2 needs further study. </plain></SENT>
<SENT sid="88" pm="."><plain>Previous studies have highlighted the anti-inflammatory role of SIRT3 in obesity-related diseases, including insulin resistance. </plain></SENT>
<SENT sid="89" pm="."><plain>The function of SIRT3 in inflammasome regulation largely depends on SIRT3-mediated activation of MnSOD and suppression of oxidative stress. </plain></SENT>
<SENT sid="90" pm="."><plain>These findings implicate that the SIRT1-SIRT3 indirectly regulate the activation of the NLRP3 inflammasome, which may be involved in the modulation of insulin resistance. </plain></SENT>
<SENT sid="91" pm="."><plain>However, whether Sirtuins directly regulate inflammasome remains unknown. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="92" pm="."><plain>Sirtuins, Inflammation and Insulin Resistance </plain></SENT>
</text></title><p><text><SENT sid="93" pm="."><plain>The roles of Sirtuins in inflammation significantly contribute to their functions during insulin resistance. </plain></SENT>
<SENT sid="94" pm="."><plain>For instance, activation of SIRT1 leads to the repression of JNK and IKK inflammatory pathways greatly and subsequently improves glucose tolerance, reduced hyperinsulinemia, and enhanced systemic insulin sensitivity (40). </plain></SENT>
<SENT sid="95" pm="."><plain>SIRT1 also controls the inflammatory status of macrophages and T lymphocytes to regulate the metabolism (insulin sensitivity) and inflammation of adipose tissues in obese mice (41, 75–77). </plain></SENT>
<SENT sid="96" pm="."><plain>In addition, SIRT6 is important for macrophage activation and TNFα production (78). </plain></SENT>
<SENT sid="97" pm="."><plain>Myeloid Sirt6 deficiency causes insulin resistance in HFD–fed mice by eliciting macrophage polarization toward an M1 phenotype (79), and facilitates the development of HFD-induced atherosclerosis (80). </plain></SENT>
<SENT sid="98" pm="."><plain>Deletion of Sirt6 in T cells or myeloid-derived cells is sufficient to induce liver inflammation and fibrosis (81). </plain></SENT>
<SENT sid="99" pm="."><plain>Interestingly, SIRT1 and SIRT6 can coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response (82). </plain></SENT>
<SENT sid="100" pm="."><plain>Therefore, Sirtuins not only regulate the inflammatory pathways within the target cells (e.g., hepatocytes, skeletal muscle cells, adipocytes) to affect their insulin sensitivity but also regulate inflammatory cells infiltrated in the organs, where the Sirtuins respond to inflammatory and metabolic insults and subsequently regulate insulin sensitivity and disease by targeting inflammatory cell activation and differentiation. </plain></SENT>
<SENT sid="101" pm="."><plain>Notably, the Sirtuins may also cooperate in diverse types of cells or within the same type of cell during inflammation-associated insulin resistance. </plain></SENT>
</text></p></sec></sec><sec id="s3"><title><text><SENT sid="102" pm="."><plain>Sirtuins in Mitochondrial Dysfunction </plain></SENT>
</text></title><p><text><SENT sid="103" pm="."><plain>Mitochondria are the primary site for ATP generation and ROS production. </plain></SENT>
<SENT sid="104" pm="."><plain>Mitochondrial dysfunction results in decreased ATP production, increased ROS production and accumulated mitochondrial DNA damage, which contribute to insulin resistance (5). </plain></SENT>
<SENT sid="105" pm="."><plain>Cells eliminate ROS by expressing endogenous antioxidant enzymes, including manganese superoxide dismutase (MnSOD), catalase, glutathione peroxidase (GPX) and glutathione reductase (GRx) (83, 84). </plain></SENT>
<SENT sid="106" pm="."><plain>An imbalance between the production of ROS and antioxidant enzymes leads to oxidative stress, which has been implicated in the pathogenesis of insulin resistance, obesity, and diabetes (1, 85). </plain></SENT>
</text></p><sec><title><text><SENT sid="107" pm="."><plain>SIRT1 </plain></SENT>
</text></title><p><text><SENT sid="108" pm="."><plain>There are fewer mitochondria in muscles of T2DM patients than those of insulin-sensitive individuals (86). </plain></SENT>
<SENT sid="109" pm="."><plain>Marked reduction of oxidative phosphorylation in the mitochondria can be detected in the liver and skeletal muscle of T2DM patients and insulin-resistant individuals (87, 88). </plain></SENT>
<SENT sid="110" pm="."><plain>Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a transcriptional coactivator that regulates mitochondrial biogenesis and respiration (89, 90). </plain></SENT>
<SENT sid="111" pm="."><plain>SIRT1 has been shown to deacetylate PGC-1α at several lysine residues and regulates PGC-1α activity, which activates the transcription of genes involved in mitochondrial biogenesis (91). </plain></SENT>
<SENT sid="112" pm="."><plain>SIRT1 activator resveratrol promotes PGC-1α activity and increases the number of mitochondria in muscle cells, which improves mitochondrial function and protects mice against diet-induced obesity and insulin resistance (92). </plain></SENT>
<SENT sid="113" pm="."><plain>In addition to mitochondria biogenesis, SIRT1 regulates mitochondrial function through clearance of damaged mitochondria (93). </plain></SENT>
<SENT sid="114" pm="."><plain>Mechanistically, SIRT1 binds to and deacetylates autophagy regulators (including ATG5, ATG7, and ATG8) to induce mitochondria autophagy or mitophagy (93). </plain></SENT>
<SENT sid="115" pm="."><plain>SIRT1-mediated deacetylation of FoxO1 and FoxO3a is also known to induce the expression of autophagy pathway components (94, 95). </plain></SENT>
<SENT sid="116" pm="."><plain>Accumulating evidence has shown that SIRT1 safeguards cells from oxidative stress. </plain></SENT>
<SENT sid="117" pm="."><plain>SIRT1 reduces ros production by deacetylating and activating FoxO3a to upregulate expression of MnSOD and catalase (95, 96). </plain></SENT>
<SENT sid="118" pm="."><plain>SIRT1 promotes the transcriptional activity of Nuclear factor (erythroid-derived 2)-like 2 (NRF2) by deacetylating it and upregulates the expression of NRF2 target antioxidant genes, including MnSOD, catalase, glutathione, and heme oxygenase-1 (HO-1) (97). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="119" pm="."><plain>SIRT2 </plain></SENT>
</text></title><p><text><SENT sid="120" pm="."><plain>Oxidative stress increases SIRT2 expression in vivo and in vitro (98, 99). </plain></SENT>
<SENT sid="121" pm="."><plain>SIRT2 can bind to FoxO3a and deacetylate it, leading to an increase in FoxO3a transcriptional activity, upregulation of the expression of FoxO target genes such as MnSOD, Bim, and p27Kip1, and a consequent decrease in ROS generation (98). </plain></SENT>
<SENT sid="122" pm="."><plain>Nicotinamide adenine dinucleotide phosphate (NADPH) is a functionally important metabolite that is required to generate the reduced form of glutathione (GSH) to maintain cellular redox potential. </plain></SENT>
<SENT sid="123" pm="."><plain>In response to oxidative stimuli, SIRT2 deacetylates and activates glucose 6-phosphate dehydrogenase (G6PD), a key enzyme in the pentose phosphate pathway (PPP), resulting in increased cytosolic NADPH to attenuate oxidative damage (100). </plain></SENT>
<SENT sid="124" pm="."><plain>Similarly, oxidative stress increases the glycolytic enzyme phosphoglycerate mutase (PGAM)-SIRT2 interaction, leading to deacetylation and activation of PGAM, which increases the cellular NADPH level to counteract oxidative damage (101). </plain></SENT>
<SENT sid="125" pm="."><plain>Lysine 4-oxononanoylation (4-ONylation) is a newly discovered histone posttranslational modification that disrupts the interaction between histone H3 and DNA, thereby preventing nucleosome assembly under oxidative stress (102). </plain></SENT>
<SENT sid="126" pm="."><plain>SIRT2 was reported to remove the 4-oxononanoyl (4-ONyl) lysine groups on histones and attenuate the negative impact of protein 4-ONylation caused by oxidative stress (103). </plain></SENT>
<SENT sid="127" pm="."><plain>This study provides novel evidence that SIRT2 may exert antioxidation effects through epigenetic modification. </plain></SENT>
<SENT sid="128" pm="."><plain>Oxidative stress is not completely caused by mitochondria, and whether SIRT2 can influence oxidative stress by regulating mitochondrial function is unclear. </plain></SENT>
</text></p><p><text><SENT sid="129" pm="."><plain>Interestingly, a recent work by Liu and colleagues observed that SIRT2 can localize to the inner mitochondrial membrane of mouse central nervous system cells and that the acetylation of several metabolic mitochondrial proteins is altered in Sirt2-deficient mice. </plain></SENT>
<SENT sid="130" pm="."><plain>In mice, deletion of Sirt2 causes mitochondrial morphological changes, increases oxidative stress and decreases ATP production in MEFs and brain tissues (104), indicating that SIRT2 may deacetylate antioxidant enzymes in the mitochondria directly. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="131" pm="."><plain>SIRT3 </plain></SENT>
</text></title><p><text><SENT sid="132" pm="."><plain>SIRT3, a central mitochondrial deacetylase, deacetylates, and activates mitochondrial enzymes to regulate mitochondrial metabolism, oxidative stress, cell survival, and longevity (105). </plain></SENT>
<SENT sid="133" pm="."><plain>SIRT3 has been shown to play a pivotal role in maintaining mitochondrial function and ROS homeostasis. </plain></SENT>
<SENT sid="134" pm="."><plain>For example, SIRT3 deacetylates complex I and complex II of the electron transport chain to promote electron transport and regulate energy homeostasis (106, 107). </plain></SENT>
<SENT sid="135" pm="."><plain>SIRT3 deacetylates cyclophilin D (CypD), the regulatory component of the mitochondrial permeability transition pore (mPTP), preventing opening of the mPTP and mitochondrial dysfunction (108). </plain></SENT>
<SENT sid="136" pm="."><plain>SIRT3 binds to and deacetylates 8-oxoguanine-DNA glycosylase 1 (OGG1), a DNA repair enzyme that excises 7,8-dihydro-8-oxoguanine from the damaged genome, resulting in the repair of mitochondrial DNA (mtDNA) damage, protection of mitochondrial integrity, defense against mitochondrial dysfunction and prevention of stress-induced cellular apoptosis (109). </plain></SENT>
<SENT sid="137" pm="."><plain>In contrast, Sirt3 deficiency has been linked to increased ROS production (110, 111). </plain></SENT>
<SENT sid="138" pm="."><plain>The antioxidant action of SIRT3 involves MnSOD and mitochondrial isocitrate dehydrogenase 2 (IDH2). </plain></SENT>
<SENT sid="139" pm="."><plain>SIRT3 has been shown to block cardiac hypertrophy by deacetylating FOXO3a and upregulating the expression of FOXO3a target genes such as MnSOD and catalase, decreasing ROS generation (112). </plain></SENT>
<SENT sid="140" pm="."><plain>Notably, the antioxidative action of SIRT3 may also be attributed to its direct deacetylation and promotion of the enzyme activity of MnSOD. </plain></SENT>
<SENT sid="141" pm="."><plain>SIRT3 deacetylates two critical lysine residues (K53 and K89) of MnSOD that promote MnSOD antioxidation activity, thereby reducing cellular ROS (113). </plain></SENT>
<SENT sid="142" pm="."><plain>Direct deacetylation of lysine residues, including K68 and K122 by SIRT3, also increases the enzyme activity of MnSOD and decreases ROS production (114, 115). </plain></SENT>
<SENT sid="143" pm="."><plain>In addition to MnSOD, SIRT3 directly deacetylates and activates mitochondrial IDH2, which results in increased NADPH levels and an increased ratio of reduced to oxidized GSH in mitochondria, thus protecting cells from oxidative stress-induced damage (110, 116). </plain></SENT>
<SENT sid="144" pm="."><plain>These studies suggest that SIRT3 activity is necessary to prevent mitochondrial dysfunction and reduce oxidative stress. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="145" pm="."><plain>SIRT4 </plain></SENT>
</text></title><p><text><SENT sid="146" pm="."><plain>SIRT4 functions as an efficient mitochondrial ADP-ribosyl transferase that negatively impacts gene expression and various metabolic processes in mitochondria. </plain></SENT>
<SENT sid="147" pm="."><plain>Our previous work demonstrated that SIRT4 promotes angiotensin II-induced development of cardiac hypertrophy by inhibiting the interaction of SIRT3 and MnSOD, which increases MnSOD acetylation levels, decreases its activity and leads to elevated ROS accumulation (117). </plain></SENT>
<SENT sid="148" pm="."><plain>SIRT4 may play a role different from that of SIRT3 in regulating mitochondrial function and oxidative stress. Sirt4 deficiency in vivo and in vitro increases the expression of genes involved in fatty acid β-oxidation and oxidative phosphorylation, thus enhancing fatty acid oxidation and mitochondrial respiration in liver and muscle (118, 119). </plain></SENT>
<SENT sid="149" pm="."><plain>SIRT4 increases stress-induced mitochondrial ROS production and interacts with the long form of GTPase optic atrophy 1 (L-OPA1) to promote mitochondrial fusion, thereby inhibiting mitophagy and decreasing the removal of dysfunctional mitochondria (120). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="150" pm="."><plain>SIRT5 </plain></SENT>
</text></title><p><text><SENT sid="151" pm="."><plain>SIRT5 functions to deacetylate, demalonylate, and desuccinylate multiple proteins in mitochondria (19). </plain></SENT>
<SENT sid="152" pm="."><plain>SIRT5 is involved in the regulation of mitochondrial fatty acid β-oxidation, the urea cycle, and cellular respiration (84, 121). </plain></SENT>
<SENT sid="153" pm="."><plain>SIRT5 binds to, desuccinylates and activates copper-zinc superoxide dismutase 1 (SOD1) to eliminate ROS (122). </plain></SENT>
<SENT sid="154" pm="."><plain>Moreover, SIRT5 desuccinylates IDH2 and deglutarylates G6PD, thus activating both NADPH-producing enzymes to scavenge ROS (123). </plain></SENT>
<SENT sid="155" pm="."><plain>SIRT5 also binds, desuccinylates and inhibits the activity of the glycolysis enzyme PKM2, which facilitates the diversion of glucose metabolites into the pentose phosphate shunt and then produces sufficient NADPH to eliminate ROS (123). </plain></SENT>
<SENT sid="156" pm="."><plain>Interestingly, a very recent study showed that SIRT5 is present in peroxisomes and can bind, desuccinylate and inhibit ACOX1, the first and rate-limiting enzyme in fatty acid β-oxidation and a major producer of H2O2, attenuating peroxisome-induced oxidative stress (124). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="157" pm="."><plain>SIRT6 </plain></SENT>
</text></title><p><text><SENT sid="158" pm="."><plain>SIRT6 plays an important role in DNA repair, genomic stability, and cellular senescence, however, the role of SIRT6 in oxidative stress has not been well clarified. </plain></SENT>
<SENT sid="159" pm="."><plain>According to recent studies, SIRT6 is believed to protect cells against oxidative stress. </plain></SENT>
<SENT sid="160" pm="."><plain>Pan et al. (125) found that SIRT6 serves as an NRF2 coactivator by interacting with NRF2 and RNA polymerase II to transactivate NRF2-regulated antioxidant genes, including HO-1. </plain></SENT>
<SENT sid="161" pm="."><plain>SIRT6 activates AMPK-FoxO3a axis to initiate expression of MnSOD and catalase and protects cardiomyocytes against ischemia/reperfusion-induced injury (126). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="162" pm="."><plain>SIRT7 </plain></SENT>
</text></title><p><text><SENT sid="163" pm="."><plain>Sirt7 deficiency in mice induces multisystemic mitochondrial dysfunction (127). </plain></SENT>
<SENT sid="164" pm="."><plain>SIRT7 deacetylates GABPβ1, a master regulator of nuclear-encoded mitochondrial genes, enables it to form the transcriptionally active GABPa/GABPβ heterotetramer, and promotes mitochondria function (127). </plain></SENT>
<SENT sid="165" pm="."><plain>Additionally, the mitochondrial unfolded protein response [UPR(mt)] is mediated by the interplay of SIRT7 and NRF1 and is coupled to cellular energy metabolism and proliferation (128). </plain></SENT>
</text></p></sec></sec><sec id="s4"><title><text><SENT sid="166" pm="."><plain>Sirtuins in Insulin Signaling Pathways </plain></SENT>
</text></title><sec><title><text><SENT sid="167" pm="."><plain>Insulin Secretion </plain></SENT>
</text></title><p><text><SENT sid="168" pm="."><plain>Under the condition of insulin resistance, normal pancreatic β cells increase the production of insulin to maintain blood glucose levels. </plain></SENT>
<SENT sid="169" pm="."><plain>However, this compensatory response fails, and relative insulin insufficiency develops. </plain></SENT>
<SENT sid="170" pm="."><plain>Then, glucose tolerance is impaired, and T2DM eventually occurs. </plain></SENT>
<SENT sid="171" pm="."><plain>SIRT1, SIRT4, and SIRT6 reportedly regulate pancreatic β cell function (Figure 1) (24, 129, 130). </plain></SENT>
<SENT sid="172" pm="."><plain>According to accumulating evidence, SIRT1 and SIRT6 repress pancreatic β cell dysfunction, attenuating the development of T2DM. β cell-specific SIRT1 transgenic mice exhibit enhanced insulin secretion and improved glucose tolerance to high glucose stimulation (131). </plain></SENT>
<SENT sid="173" pm="."><plain>Mechanistically, through repressing UCP2 expression, SIRT1 enhances ATP production in pancreatic β cells, to shut down the potassium channel, resulting in the influx of calcium and finally the secretion of insulin (131, 132). </plain></SENT>
<SENT sid="174" pm="."><plain>SIRT1 can induce NeuroD and MafA expression via deacetylating and activating FoxO1, which protects pancreatic β cells against oxidative damage and preserves pancreatic β cells function (133). </plain></SENT>
<SENT sid="175" pm="."><plain>In contrast to SIRT1 and SIRT6, SIRT4 functions as a negative regulator of insulin secretion in β cells. </plain></SENT>
<SENT sid="176" pm="."><plain>Glutamate dehydrogenase (GDH) promotes the metabolism of glutamate and glutamine, generating ATP to further promote insulin secretion. </plain></SENT>
<SENT sid="177" pm="."><plain>In pancreatic β cells, SIRT4 represses the activity of GDH by ADP-ribosylation, thereby downregulating insulin secretion in response to amino acids under calorie-sufficient conditions (20). </plain></SENT>
<SENT sid="178" pm="."><plain>SIRT4 also controls leucine oxidation to regulate insulin secretion (134). </plain></SENT>
<SENT sid="179" pm="."><plain>Given that SIRT3 deacetylases GDH and increases its activity in hepatocytes (135), SIRT3 may function in β cell mitochondria to promote insulin secretion. </plain></SENT>
<SENT sid="180" pm="."><plain>Recent studies have provided evidence to support this notion. </plain></SENT>
<SENT sid="181" pm="."><plain>Caton et al. observed that SIRT3 expression markedly decreases in islets isolated from T2DM patients, as well as in mouse islets or INS1 cells (136). Sirt3 knockdown in INS1 cells results in increased production of cellular ROS and IL-1β, increased β cell apoptosis and reduced insulin secretion (136). </plain></SENT>
<SENT sid="182" pm="."><plain>SIRT3 deficiency predisposes pancreatic β cells to oxidative stress-induced dysfunction and reduces glucose-induced insulin secretion (137). </plain></SENT>
<SENT sid="183" pm="."><plain>By contrast, SIRT3 overexpression inhibits ER stress and attenuates palmitate-induced pancreatic β cell dysfunction (138, 139). </plain></SENT>
<SENT sid="184" pm="."><plain>Therefore, SIRT3 and SIRT4 play opposing roles in regulating insulin secretion in pancreatic β cells. </plain></SENT>
<SENT sid="185" pm="."><plain>In addition, insulin secretion impairment is observed in Sirt6 knockout pancreatic β cells, which is mediated by suppression of the FoxO1-Pdx1-Glut2 pathway (140). Sirt6 deletion in pancreatic β cells also reduces ATP production and increases mitochondrial damage which induces cell apoptosis and impairs glucose-stimulated insulin secretion (129, 141). β cell-specific Sirt6-ko mice are glucose intolerance and are defective in glucose-stimulated insulin secretion, in spite do not show abnormality in endocrine morphology, pancreatic β cell mass or insulin production (130). Sirt6 deficiency also results in aberrant upregulation of thioredoxin-interacting protein (TXNIP) in pancreatic β cells, which inhibits insulin secretion (130). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="186" pm="."><plain>Sirtuins regulates insulin secretion of pancreatic beta cells. </plain></SENT>
<SENT sid="187" pm="."><plain>In the nucleus, SIRT1 induces insulin secretion through the reduction of UCP2 expression and the enhancement of depolarization in pancreatic β cells, while SIRT6 deacetylates FOXO1 and promotes the expression of GLUT2, which facilitates glucose uptake and insulin secretion. </plain></SENT>
<SENT sid="188" pm="."><plain>In the mitochondria, SIRT4 promotes the ADP-ribosylation and inactivation of GDH, leading the repression of ATP generation and inhibition of insulin secretion. </plain></SENT>
<SENT sid="189" pm="."><plain>UCP2, uncoupling protein 2; Glu, glutamate; GDH, glutamate dehydrogenase; GLUT2, glucose transporter 2; α-KG, alpha-ketoglutarate. </plain></SENT>
</text></p></caption><graphic xlink:href="fendo-09-00748-g0001"/></fig></SecTag></sec><sec><title><text><SENT sid="190" pm="."><plain>Insulin Signaling Pathway </plain></SENT>
</text></title><p><text><SENT sid="191" pm="."><plain>Insulin resistance, the inability of cells to efficiently respond to a normal dose of insulin, is caused by impaired insulin signaling and postreceptor intracellular defects (4). </plain></SENT>
<SENT sid="192" pm="."><plain>Insulin binding to its receptor results in IR phosphorylating itself and several intracellular substrates. </plain></SENT>
<SENT sid="193" pm="."><plain>The phosphorylated substrates interact with intracellular effectors, leading to the activation of the PI3K-Akt pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which controls cell growth and differentiation (4, 142). </plain></SENT>
<SENT sid="194" pm="."><plain>Impaired Akt activation is a key factor in metabolic disorders involving insulin resistance. </plain></SENT>
<SENT sid="195" pm="."><plain>Accumulating evidence suggests that Sirtuins participate in insulin signaling in target cells (Figure 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" position="float"><label>Figure 2</label><caption><p><text><SENT sid="196" pm="."><plain>Sirtuins regulates insulin signaling pathways. </plain></SENT>
<SENT sid="197" pm="."><plain>In nutrient enough conditions, insulin and insulin-like growth factors activate the IRS-PI3K-AKT signaling and downstream FOXO and mTOR signaling to regulate multiple aspects of metabolism, survival, mitochondrial homeostasis, nuclear transcriptional events, and other cellular behaviors. </plain></SENT>
<SENT sid="198" pm="."><plain>The insulin receptor activation is inhibited by PTPN1, which is repressed by SIRT1. </plain></SENT>
<SENT sid="199" pm="."><plain>SIRT1 also deacetylates IRS2 and represses IRS1 phosphorylation and PI3K-AKT activation. </plain></SENT>
<SENT sid="200" pm="."><plain>SIRT1 and SIRT2 also deacetylate AKT to activate its activation directly, while SIRT7 indirectly inhibits AKT activation by deacetylating FKBP51. </plain></SENT>
<SENT sid="201" pm="."><plain>Under energetic stress or caloric restriction, multiple members of the Sirtuins family are activated. </plain></SENT>
<SENT sid="202" pm="."><plain>SIRT1, SIRT2, SIRT3, and SIRT6 can directly deacetylate FOXOs (FOXO1 and FOXO3a), while SIRT1 and SIRT2 activate the LKB1-AMPK signaling to activate FOXO and inhibit mTOR signaling. </plain></SENT>
<SENT sid="203" pm="."><plain>IGF, insulin-like growth factor; IRS, insulin receptor substrate; PTPN1, tyrosine-protein phosphatase non-receptor type 1; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; mTOR, mammalian target of rapamycin; AMPK, AMP-activated protein kinase; LKB1, liver kinase B1; FKBP51, FK506-binding protein 51; GSK3β, glycogen synthase kinase-3 beta. </plain></SENT>
</text></p></caption><graphic xlink:href="fendo-09-00748-g0002"/></fig></SecTag><p><text><SENT sid="204" pm="."><plain>SIRT1 positively regulates insulin signaling and Akt activation at multiple levels. </plain></SENT>
<SENT sid="205" pm="."><plain>SIRT1 represses transcription of PTPN1, a negative regulator of the insulin signal transduction cascade, at the chromatin level and improves insulin sensitivity (3). </plain></SENT>
<SENT sid="206" pm="."><plain>Knockdown of Sirt1 in 3T3-L1 adipocytes increases phosphorylation of JNK, as well as serine phosphorylation of insulin receptor substrate 1 (IRS-1), which leads to decrease tyrosine phosphorylation of IRS-1, and then inhibit phosphorylation of Akt (39). </plain></SENT>
<SENT sid="207" pm="."><plain>Inhibition of SIRT1 activity reduces insulin-induced IRS-2 deacetylation, which prevents insulin-induced IRS-2 tyrosine phosphorylation (143). </plain></SENT>
<SENT sid="208" pm="."><plain>SIRT1 mediates deacetylation of Akt regulates binding of Akt to phosphatidylinositol 3,4,5-trisphosphate (PIP3) which is necessary for Akt membrane localization and activation (144). </plain></SENT>
</text></p><p><text><SENT sid="209" pm="."><plain>SIRT2 can directly regulate the insulin signaling pathway, but its role is controversial. </plain></SENT>
<SENT sid="210" pm="."><plain>SIRT2 can deacetylate and activate Akt through the Akt/glycogen synthase kinase-3β (GSK3β)/β-catenin signaling pathway, finally resulting in aberrant proliferation and survival of myeloid leukemia cells and epithelial-mesenchymal transition of HCC (145, 146). </plain></SENT>
<SENT sid="211" pm="."><plain>Interestingly, Ramakrishnan and colleagues showed that SIRT2 is a novel Akt interactor and is required for optimal Akt activation under normal conditions (147). </plain></SENT>
<SENT sid="212" pm="."><plain>Pharmacological or genetic inhibition of SIRT2 decreases Akt activation in 3T3-L1 preadipocytes and HeLa cells, whereas SIRT2 overexpression enhances the activation of Akt and its downstream targets, such as GSK3 and p70-S6-kinase (147). </plain></SENT>
<SENT sid="213" pm="."><plain>Insulin-induced Akt activation requires Akt binding to inositol 1,4,5-trisphosphate, which leads to Akt conformational changes and facilitates its phosphorylation by PDK1 and mTORC1 (147). </plain></SENT>
<SENT sid="214" pm="."><plain>Acetylation at Lys20 blocks Akt activation by restricting the binding of Akt to inositol 1,4,5-trisphosphate (144). </plain></SENT>
<SENT sid="215" pm="."><plain>However, the authors were unable to detect Akt acetylation in the experiment, and they could not determine whether the effects of SIRT2 on Akt are dependent on changing the acetylation level of Akt (147). </plain></SENT>
<SENT sid="216" pm="."><plain>However, the opposite results have also been reported. </plain></SENT>
<SENT sid="217" pm="."><plain>Arora et al. reported that SIRT2 is upregulated in insulin-resistant skeletal muscle cells, and inhibition of SIRT2 by pharmacological or genetic means improves phosphorylation of Akt and GSK3β and increases insulin-stimulated glucose uptake (148). </plain></SENT>
<SENT sid="218" pm="."><plain>Similarly, in insulin-resistant neuro-2a cells, inhibition of SIRT2 by pharmacological or genetic means also enhances the activity of Akt and increases insulin-stimulated glucose uptake (149). </plain></SENT>
<SENT sid="219" pm="."><plain>Therefore, SIRT2 may regulate Akt in both direct (activity-dependent) and indirect (activity-independent) manners, which may largely rely on the metabolic status of the cells. </plain></SENT>
<SENT sid="220" pm="."><plain>SIRT2 can deacetylate and regulate the function of FOxO transcription factors, which are direct Akt targets (98, 150). </plain></SENT>
<SENT sid="221" pm="."><plain>Interestingly, the Akt-independent pathway also contributes to the function of SIRT2 in the regulation of insulin sensitivity. </plain></SENT>
<SENT sid="222" pm="."><plain>TUG acetylation modulates its interaction with Golgi matrix proteins and enhances its function to trap GLUT4 storage vesicles in intracellular (151). </plain></SENT>
<SENT sid="223" pm="."><plain>Insulin mobilizes the exocytic translocation of GLUT4 glucose transporters by triggering TUG proteolysis to accelerate glucose uptake in fat and muscle. </plain></SENT>
<SENT sid="224" pm="."><plain>SIRT2-mediated TUG deacetylation controls insulin sensitivity in vivo and in vitro (151). </plain></SENT>
</text></p><p><text><SENT sid="225" pm="."><plain>The role of SIRT6 in the insulin signaling pathway is controversial. Sirt6-deficient mice die about 4 weeks of age, exhibiting severe metabolic defects, including low insulin and hypoglycemia (15). </plain></SENT>
<SENT sid="226" pm="."><plain>Xiao et al. found that Sirt6 deficiency increases Akt phosphorylation through modulating insulin signaling upstream of Akt, including insulin receptor, IRS1, IRS2, and enhances insulin signaling, leading to hypoglycemia (152). </plain></SENT>
<SENT sid="227" pm="."><plain>On the contrary, Sirt6 transgenic mice show increased insulin sensitivity in skeletal muscle and liver and exhibit enhanced insulin-induced Akt activation in gastrocnemius (153). </plain></SENT>
</text></p><p><text><SENT sid="228" pm="."><plain>In addition, SIRT7 can regulate Akt signaling. </plain></SENT>
<SENT sid="229" pm="."><plain>SIRT7 regulates the acetylation of FKBP51, which then regulates Akt activation. </plain></SENT>
<SENT sid="230" pm="."><plain>Acetylated FKBP51 enhances Akt activity by blocking its interaction with PHLPP-Akt. </plain></SENT>
<SENT sid="231" pm="."><plain>SIRT7 deacetylates FKBP51 at two major lysine residues. </plain></SENT>
<SENT sid="232" pm="."><plain>SIRT7 suppresses Akt activation and modulates cell sensitivity to genotoxic agents (154). </plain></SENT>
<SENT sid="233" pm="."><plain>The inhibitory effects of SIRT7 on Akt activation were also observed in murine hearts. </plain></SENT>
</text></p></sec></sec><sec id="s5"><title><text><SENT sid="234" pm="."><plain>Sirtuins in Insulin-Sensitive Organs </plain></SENT>
</text></title><p><text><SENT sid="235" pm="."><plain>Adipose tissue, liver, and muscle are the primary insulin-responsive organs. </plain></SENT>
<SENT sid="236" pm="."><plain>Insulin regulates blood glucose concentrations by suppressing hepatic glucose output and stimulating glucose uptake by muscle and adipose tissue. </plain></SENT>
<SENT sid="237" pm="."><plain>In addition, insulin promotes energy storage in adipose tissue, liver, and muscle by stimulating lipogenesis, glycogen, and protein synthesis but inhibiting lipolysis, glycogenolysis and protein catabolism (155). </plain></SENT>
</text></p><p><text><SENT sid="238" pm="."><plain>The impaired lipogenic/adipogenic capacity of adipose tissue leads to increased body fat mass and adverse metabolic consequences (4, 156). </plain></SENT>
<SENT sid="239" pm="."><plain>Adipose tissue is not only an excessive energy storage pot but also a highly active endocrine organ that secretes proteins, adipokines, cytokines and chemokines to influence insulin sensitivity. </plain></SENT>
<SENT sid="240" pm="."><plain>Circulating FFAs derived from adipocytes are involved in the accumulation of triglycerides and fatty acid-derived metabolites in muscle and liver, which is a contributing factor to insulin resistance (155). </plain></SENT>
<SENT sid="241" pm="."><plain>In addition, adipose tissue is an important initiator of the inflammatory response to obesity (28), and FFAs from adipose tissue are important ER stress-triggering factors (28). </plain></SENT>
</text></p><p><text><SENT sid="242" pm="."><plain>The liver, as the central organ responsible for maintaining lipid and glucose hemostasis in the body, plays a crucial role in insulin sensitivity and metabolic diseases. </plain></SENT>
<SENT sid="243" pm="."><plain>During prolonged fasting or starvation, the liver converts lipids to available energy through fatty acid oxidation and provides glucose to maintain normal blood glucose, initially by glycogenolysis and then by switching to gluconeogenesis (157, 158). </plain></SENT>
<SENT sid="244" pm="."><plain>Under energy abundance conditions, the liver promotes glycogenesis and lipogenesis to store energy. </plain></SENT>
<SENT sid="245" pm="."><plain>Insulin stimulates glycogen accumulation and blocks gluconeogenesis and glycogenolysis in the liver to suppress hepatic glucose output (155, 158, 159). </plain></SENT>
<SENT sid="246" pm="."><plain>In the condition of insulin resistance, suppression of hepatic glucose output is impaired, while increased FFA from adipocytes leads to ectopic lipid accumulation in the liver, which exacerbates insulin resistance (29). </plain></SENT>
</text></p><p><text><SENT sid="247" pm="."><plain>Skeletal muscle is the major site for insulin-stimulated glucose disposal in vivo as well as the main energy consumer of lipid catabolism that strongly influences whole-body lipid metabolism (155, 160). </plain></SENT>
<SENT sid="248" pm="."><plain>The ability to switch between glucose and lipid oxidation is crucial for skeletal muscle to maintain physiological function and metabolic hemostasis (161). </plain></SENT>
<SENT sid="249" pm="."><plain>Intramuscular fatty acid metabolite accumulation may cause insulin resistance (162). </plain></SENT>
</text></p><p><text><SENT sid="250" pm="."><plain>The functions of Sirtuins in regulating glucose and lipid metabolism as well as insulin sensitivity have been widely investigated in adipose tissue, liver and skeletal muscles (Figure 3). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F3" position="float"><label>Figure 3</label><caption><p><text><SENT sid="251" pm="."><plain>Sirtuins regulates metabolism in insulin-target organs. </plain></SENT>
<SENT sid="252" pm="."><plain>The functions of Sirtuins in the regulation of glucose and fatty acid metabolism in the liver, adipose tissue, and skeletal muscle. </plain></SENT>
<SENT sid="253" pm="."><plain>The (–) indicates Sirtuin represses the activation/expression of this target, whereas (+) indicates Sirtuin promotes the activation/expression of the target. </plain></SENT>
<SENT sid="254" pm="."><plain>The green background indicates Sirtuin promotes the biological process whereas the pink background indicates the Sirtuin represses the biological process. </plain></SENT>
<SENT sid="255" pm="."><plain>PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; TORC2, CREB regulated transcription coactivator 2; PPARα, peroxisome proliferator-activated receptor alpha; SREBP1c, Sterol response element-binding protein 1c; AMPK, AMP-activated protein kinase; HIF1α, hypoxia-inducible factor 1 alpha; PGAM-1, phosphoglycerate mutase 1; CRTC2, CREB regulated transcription coactivator 2; PPARγ, peroxisome proliferator-activated receptor gamma; Prdm16, PR domain containing 16; PEPCK1, phosphoenolpyruvate carboxykinase 1; LCAD, long-chain acyl-CoA dehydrogenase; PDH, pyruvate dehydrogenase; IDH2, isocitrate dehydrogenase; NDUFA9, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9; SDH, succinate dehydrogenase; HK2, hexokinase 2; MCD, malonyl-CoA decarboxylase; ECHA, trifunctional enzyme subunit alpha; HCDH, hydroxyacyl-Coenzyme A dehydrogenase; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; SREBP-2, sterol regulatory element-binding protein 2; ACC, acetyl-CoA carboxylase; SCD, stearoyl-CoA desaturase; FAS, fatty acid synthase; GK, glucokinase; GCN5, general control non-repressed protein 5; KIF5C, kinesin heavy chain isoform 5C; GABPβ1, GA binding protein β1; DCAF1/DDB1/GUL4B, DDB1-CUL4-associated factor 1 (DCAF1)/damage-specific DNA binding protein 1 (DDB1)/cullin 4B (CUL4B) complex; PGK1, phosphoglycerate kinase 1; G6PC, glucose-6-phosphatase, catalytic subunit; GKRP, glucokinase regulatory protein. </plain></SENT>
</text></p></caption><graphic xlink:href="fendo-09-00748-g0003"/></fig></SecTag><sec><title><text><SENT sid="256" pm="."><plain>SIRT1 and Insulin-Sensitive Organs </plain></SENT>
</text></title><sec><title><text><SENT sid="257" pm="."><plain>SIRT1 Regulates Fatty Acid and Glucose Metabolism in the Liver </plain></SENT>
</text></title><p><text><SENT sid="258" pm="."><plain>The role of SIRT1 in regulating hepatic gluconeogenesis is controversial under the condition of calorie restriction. </plain></SENT>
<SENT sid="259" pm="."><plain>Resveratrol has been shown to improve glucose homeostasis in insulin-resistant mice by reducing hepatic gluconeogenesis and increase insulin sensitivity in adipose tissue, skeletal muscle and liver (163). </plain></SENT>
<SENT sid="260" pm="."><plain>On the contrary, resveratrol causes nuclear translocation of FoxO1 in hepatocytes via SIRT1-dependent deacetylation, which leads to activation of gluconeogenesis and increased hepatic glucose output (164). </plain></SENT>
<SENT sid="261" pm="."><plain>Pyruvate induces SIRT1 protein in the liver during fasting, and once SIRT1 is induced, which can increase gluconeogenic genes expression and promote hepatic glucose output through interacting and deacetylating PGC-1α (165). </plain></SENT>
<SENT sid="262" pm="."><plain>Conversely, during prolonged fasting, SIRT1 deacetylates CREB regulated transcription coactivator 2 (CRTC2) and promotes its ubiquitin-dependent degradation to inhibit gluconeogenic gene expression, leading to decreased hepatic glucose output (166). </plain></SENT>
<SENT sid="263" pm="."><plain>On the other hand, upregulation of FOXO1 and PGC-1α activity by SIRT1 leads to activation of gluconeogenic gene expression in hepatic cells and increase hepatic glucose production (157, 166). </plain></SENT>
<SENT sid="264" pm="."><plain>In addition, SIRT1 regulates the activity of PGC-1α, and glycolytic enzyme phosphoglycerate mutase-1 (PGAM1), inducing repression of glycolytic genes in response to fasting (165, 167). </plain></SENT>
<SENT sid="265" pm="."><plain>These studies suggest an important role of SIRT1 in maintaining energy balance under fasting. </plain></SENT>
<SENT sid="266" pm="."><plain>Liver-specific Sirt1 ko mice develop hepatic steatosis when underwent fasting and obesity when fed with HFD in insulin-dependent and independent manners (38, 168). Sirt1 transgenic mice show better glucose tolerance and insulin sensitivity and are almost entirely protected from hepatic steatosis with HFD treatment (37, 169). </plain></SENT>
<SENT sid="267" pm="."><plain>On one hand, SIRT1 deacetylates and activates PGC-1α, increasing fatty acid β-oxidation in the liver (38). </plain></SENT>
<SENT sid="268" pm="."><plain>On the other hand, SIRT1 plays an important role in inhibiting lipogenesis in the liver. For example, resveratrol can increase the levels of sterol regulatory element-binding protein (SREBP), a critical regulator of lipid and sterol homeostasis in eukaryotes, in livers of alcohol-treated mice and alleviate alcoholic fatty liver (170). </plain></SENT>
<SENT sid="270" pm="."><plain>SRT1720, a SIRT1 activator, ameliorates fatty liver through suppressing the expression of lipogenic enzymes, including SREBP-1c, acetyl-CoA carboxylase, and fatty acid synthase, in obesity and insulin resistant mice (171). </plain></SENT>
<SENT sid="271" pm="."><plain>SIRT1 can directly deacetylate SREBP, and control SREBP protein stability via SREBP ubiquitination, leading to attenuating SREBP target lipogenic gene expression and inhibiting lipid synthesis and fat storage (172). </plain></SENT>
<SENT sid="272" pm="."><plain>Otherwise, SIRT1 activation by polyphenols acts as an upstream regulator in the LKB1/AMPK signaling axis, resulting in repression expression of acetyl-CoA carboxylase and fatty acid synthase and reduction of lipid accumulation in hepatocytes (173). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="273" pm="."><plain>SIRT1 Regulates Adipocyte Differentiation and Adipogenesis </plain></SENT>
</text></title><p><text><SENT sid="274" pm="."><plain>PPARγ and CCAAT/enhancer-binding protein α (C/EBPα) are master regulators of adipogenesis (156, 174). </plain></SENT>
<SENT sid="275" pm="."><plain>SIRT1 overexpression inhibits the expression of PPARγ and C/EBPα in 3T3-L1 adipocytes (175). </plain></SENT>
<SENT sid="276" pm="."><plain>SIRT1 represses PPARγ by docking with its cofactors nuclear receptor co-repressor (NCoR) and silencing mediator of retinoid and thyroid hormone receptors (SMRT) and suppresses adipogenesis (175). </plain></SENT>
<SENT sid="277" pm="."><plain>In differentiated fat cells, upregulation of SIRT1 by resveratrol triggers lipolysis and loss of fat, but SIRT1 inhibitor nicotinamide reduces the release of free fatty acid (175). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="278" pm="."><plain>SIRT1 Regulates Lipid Metabolism in Skeletal Muscle </plain></SENT>
</text></title><p><text><SENT sid="279" pm="."><plain>There is a strong correlation between the presence of intramyocellular lipid in skeletal muscle and liver and progression of T2DM (176, 177). </plain></SENT>
<SENT sid="280" pm="."><plain>Fasting induces PGC-1α deacetylation by SIRT1 in skeletal muscle, and that is required for activation of mitochondrial fatty acid oxidation genes (178). </plain></SENT>
<SENT sid="281" pm="."><plain>SIRT1 overexpression protects C2C12 myotubes against fatty acid-induced insulin resistance through transcriptional repression of PTP1B (3). </plain></SENT>
<SENT sid="282" pm="."><plain>In skeletal muscle, SIRT1 acts downstream of AMPK signaling, deacetylates and modulates the activity of PGC-1α, FOXO1, and FOXO3a to inhibit lipogenesis and promote energy consumption (179). </plain></SENT>
<SENT sid="283" pm="."><plain>SIRT1 overexpression or resveratrol treatment increases insulin-induced Akt phosphorylation and activation via interacting with the PI3K adapter subunit p85 (180). </plain></SENT>
<SENT sid="284" pm="."><plain>These studies suggest SIRT1 plays a positive role in ameliorating insulin sensitivity in skeletal muscle. </plain></SENT>
<SENT sid="285" pm="."><plain>However, several studies have demonstrated that skeletal muscle-specific overexpression of SIRT1 does not enhance whole-body energy expenditure or skeletal muscle insulin sensitivity under normal or overfeeding conditions (181, 182). </plain></SENT>
<SENT sid="286" pm="."><plain>These controversial results suggest SIRT1 in other metabolic tissues, such as adipose tissue, liver or intestinal tissue, may play a role in the metabolic benefits of SIRT1 activation (183). </plain></SENT>
<SENT sid="287" pm="."><plain>Notably, high-intensity interval training increases SIRT1 activity in human skeletal muscle and mice with muscle-specific inactivation of the SIRT1 deacetylase domain displayed reduced myofiber size, impaired muscle regeneration, and derepression of muscle developmental genes (184, 185). </plain></SENT>
<SENT sid="288" pm="."><plain>Therefore, SIRT1-mediated metabolic balance is important for skeletal muscle homeostasis and regeneration. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="289" pm="."><plain>SIRT2 and Insulin-Sensitive Organs </plain></SENT>
</text></title><sec><title><text><SENT sid="290" pm="."><plain>SIRT2 Regulates Adipocyte Differentiation and Adipogenesis </plain></SENT>
</text></title><p><text><SENT sid="291" pm="."><plain>SIRT2 is widely distributed and has been detected in a wide range of metabolic tissues, including the brain, muscle, liver, pancreas and adipose tissue. </plain></SENT>
<SENT sid="292" pm="."><plain>SIRT2 expression is regulated by metabolic status. </plain></SENT>
<SENT sid="293" pm="."><plain>For instance, the expression of SIRT2 is elevated in the white adipose tissue (WAT) of cr mice (98). </plain></SENT>
<SENT sid="294" pm="."><plain>SIRT2 gene expression increased in the peripheral blood mononuclear cells of obese subjects following an 8-week hypocaloric diet (186). </plain></SENT>
<SENT sid="295" pm="."><plain>By contrast, SIRT2 protein expression in visceral WAT from human obese subjects and a mouse model of diet-induced obesity is downregulated compared with that in WAT from lean controls (187). </plain></SENT>
<SENT sid="296" pm="."><plain>SIRT2 gene expression is significantly lower in peripheral blood mononuclear cells of obese children with insulin resistance than in those without insulin resistance (188). </plain></SENT>
<SENT sid="297" pm="."><plain>A growing body of literature has indicated that SIRT2 is involved in regulating various metabolic processes, including adipocyte differentiation, hepatic gluconeogenesis, and insulin action. </plain></SENT>
<SENT sid="298" pm="."><plain>SIRT2 mRNA is more abundant than other Sirtuins in adipose tissue in vivo and preadipocytes in culture (150), implicating the possible important role of SIRT2 in adipose tissue. </plain></SENT>
<SENT sid="299" pm="."><plain>FOXO1 acts as an adipogenesis inhibitor (189). </plain></SENT>
<SENT sid="300" pm="."><plain>In adipose tissue, FOXO1 can interact with PPARγ and negatively regulate its transcriptional activity (190) or bind to the PPARγ promoter region and suppress its expression (191). </plain></SENT>
<SENT sid="301" pm="."><plain>In mouse 3T3-L1 preadipocytes, SIRT2 interacts with and deacetylates FOXO1, which antagonizes FOXO1 phosphorylation and promotes nuclear retention of FOXO1, leading to repression of the expression of PPARγ and C/EBPα as well as genes marking terminal adipocyte differentiation, such as Glut4, aP2, and fatty acid synthase (150). </plain></SENT>
<SENT sid="302" pm="."><plain>SIRT2 also suppresses adipogenesis by deacetylating FOXO1 to promote the binding of FOXO1 to PPARγ and subsequent repression of PPARγ transcriptional activity (192). </plain></SENT>
<SENT sid="303" pm="."><plain>Increased de novo lipogenesis is an important contributor to increased adipose mass (193). </plain></SENT>
<SENT sid="304" pm="."><plain>ATP-citrate lyase (ACLY) is the building block for de novo lipid synthesis, which converts glucose-derived citrate into acetyl-CoA (194). </plain></SENT>
<SENT sid="305" pm="."><plain>ACLY is acetylated on multiple lysine residues in response to high glucose and promotes lipogenesis, while SIRT2 deacetylates and destabilizes ACLY, leading to reduced lipogenesis (195). </plain></SENT>
<SENT sid="306" pm="."><plain>Transcriptional regulators such as PPARs and the coactivator PGC-1α play key roles in the process of fatty acid β-oxidation, which determines whole-body energy expenditure (196). </plain></SENT>
<SENT sid="307" pm="."><plain>Through transcriptional repression of SIRT2, hypoxia-inducible factor 1α (HIF1α) decreases deacetylation of PGC-1α and further diminishes fatty acid β-oxidation in WAT. </plain></SENT>
<SENT sid="308" pm="."><plain>Adipocyte-specific HIF1α inactivation leads to increased expression of SIRT2 and attenuates dietary-driven obesity in mice (187). </plain></SENT>
<SENT sid="309" pm="."><plain>These studies suggest that SIRT2 contributes to the control of adipose tissue mass by inhibiting adipogenesis and lipogenesis but promoting fatty acid β-oxidation. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="310" pm="."><plain>SIRT2 Participates in Gluconeogenesis in the Liver </plain></SENT>
</text></title><p><text><SENT sid="311" pm="."><plain>SIRT2 deacetylates and subsequently increases the stability of PEPCK1, the gluconeogenic rate-limiting enzyme under conditions of glucose deprivation, leading to increased gluconeogenesis (197, 198). </plain></SENT>
<SENT sid="312" pm="."><plain>FOXO1 and PGC-1α reportedly activate the process of gluconeogenesis in the liver by increasing the transcription of gluconeogenic enzyme genes and are considered negative regulators of insulin sensitivity in the liver (199–201). </plain></SENT>
<SENT sid="313" pm="."><plain>Insulin suppresses gluconeogenesis by regulating the FOXO1-PGC-1α interaction (199). </plain></SENT>
<SENT sid="314" pm="."><plain>SIRT2 deacetylates and activates FOXO1/PGC-1α in adipocytes (150, 187, 192), which implies that SIRT2 may enhance gluconeogenesis through the FOXO1-PGC-1α pathway. </plain></SENT>
<SENT sid="315" pm="."><plain>However, whether the role of SIRT2 in gluconeogenesis depends on different nutrient conditions must be elucidated. </plain></SENT>
<SENT sid="316" pm="."><plain>In addition, the roles of SIRT2 in metabolic diseases are largely unknown. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="317" pm="."><plain>SIRT3 </plain></SENT>
</text></title><p><text><SENT sid="318" pm="."><plain>Human SIRT3 is expressed in a variety of metabolically active tissues, including muscle, liver, kidney, heart, brain, and BAT (202–204). </plain></SENT>
<SENT sid="319" pm="."><plain>The expression of SIRT3 in the liver and adipose tissue of mice increases during cr (205–208). </plain></SENT>
<SENT sid="320" pm="."><plain>A single nucleotide polymorphism in the human SIRT3 gene has been correlated with the reduced enzymatic efficiency of SIRT3 and the development of metabolic syndrome (209). </plain></SENT>
<SENT sid="321" pm="."><plain>Compared with WT mice, Sirt3-KO mice fed an HFD show accelerated obesity, insulin resistance, hyperlipidemia, and hepatic steatosis (209). </plain></SENT>
</text></p><sec><title><text><SENT sid="322" pm="."><plain>SIRT3 Participates in WAT/BAT Metabolism and Thermogenesis </plain></SENT>
</text></title><p><text><SENT sid="323" pm="."><plain>High levels of SIRT3 occur in the BAT. </plain></SENT>
<SENT sid="324" pm="."><plain>Cold exposure upregulates SIRT3 expression in the BAT. </plain></SENT>
<SENT sid="325" pm="."><plain>Increasing the expression of PGC-1α and uncoupling protein 1 (UCP1) by sustained expression of SIRT3 in brown adipocytes leads to increased thermogenesis (7, 206). </plain></SENT>
<SENT sid="326" pm="."><plain>Fatty acid β-oxidation in the BAT of Sirt3-KO mice is significantly reduced (210). </plain></SENT>
<SENT sid="327" pm="."><plain>Although SIRT3 maintains a low level in WAT (206), several studies refer to the role of SIRT3 in regulating WAT lipid metabolism. cr activates SIRT3 expression in both white and brown adipose tissue; SIRT3 expression decreases in the BAT of several lines of genetically obese mice (206). </plain></SENT>
<SENT sid="328" pm="."><plain>In a human study, SIRT3 gene expression was decreased in VAT from morbid subjects (211) and WAT from children with obesity (212). </plain></SENT>
<SENT sid="329" pm="."><plain>Although the role of SIRT3 in WAT lipid metabolism is intricate and unclear, these studies suggest that SIRT3 may play a protective role in obesity. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="330" pm="."><plain>SIRT3 Regulates Fatty Acid Oxidation in the Liver </plain></SENT>
</text></title><p><text><SENT sid="331" pm="."><plain>Sirt3-deficient mice show higher levels of fatty acid β-oxidation intermediate products and triglycerides in the liver during fasting and develop hepatic steatosis (210). </plain></SENT>
<SENT sid="332" pm="."><plain>Metabolomic analyses of fasted Sirt3-deficient mice revealed that SIRT3 is involved in fatty acid β-oxidation and modulates fatty acid β-oxidation at multiple points, such as short-chain L-3-hydroxy acyl-CoA dehydrogenase (SCHAD), very-long-chain acyl-CoA dehydrogenase (VLCAD) and 3-ketoacyl-CoA thiolase, in addition to LCAD (208). </plain></SENT>
<SENT sid="333" pm="."><plain>LCAD is a key enzyme in mitochondrial fatty acid β-oxidation, and LCAD deficiency causes hepatic steatosis and hepatic insulin resistance (213, 214). </plain></SENT>
<SENT sid="334" pm="."><plain>SIRT3 promotes hepatic fatty acid β-oxidation through deacetylation and activation of LCAD (210). </plain></SENT>
<SENT sid="335" pm="."><plain>However, hepatocyte-specific Sirt3-KO mice do not show any obvious metabolic phenotype under either chow or HFD conditions, despite a marked global hyperacetylation of mitochondrial proteins (215). </plain></SENT>
<SENT sid="336" pm="."><plain>These conflicting findings from global Sirt3-KO mice and tissue-specific KO mice suggest that the roles of SIRT3 in other cell types may be important for SIRT3-mediated metabolic effects in the liver. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="337" pm="."><plain>SIRT3 Regulates Glucose Metabolism in Skeletal Muscle </plain></SENT>
</text></title><p><text><SENT sid="338" pm="."><plain>SIRT3 expression decreases in the skeletal muscle of diabetic and HFD-fed mice (36, 216). </plain></SENT>
<SENT sid="339" pm="."><plain>CR and exercise upregulate SIRT3 expression in mouse skeletal muscle (162). </plain></SENT>
<SENT sid="340" pm="."><plain>These findings suggest that SIRT3 is involved in skeletal muscle metabolism. </plain></SENT>
<SENT sid="341" pm="."><plain>Although muscle-specific Sirt3 KO in mice shows no obvious effects on global metabolic hemostasis under normal conditions (215), striking results have been shown in global Sirt3-KO mice. </plain></SENT>
<SENT sid="342" pm="."><plain>Global Sirt3-KO mice exhibit decreased oxygen consumption and enhanced oxidative stress in skeletal muscle that leads to impaired insulin signaling (36). </plain></SENT>
<SENT sid="343" pm="."><plain>The deletion of Sirt3 in vivo and in vitro induces hyperacetylation of the pyruvate dehydrogenase (PDH) E1α subunit and leads to decreased PDH enzymatic activity (161). </plain></SENT>
<SENT sid="344" pm="."><plain>Inhibition of PDH activity reduces glucose oxidation and results in a switch to fatty acid β-oxidation, thus leading to a loss of skeletal muscle metabolic flexibility (161). </plain></SENT>
<SENT sid="345" pm="."><plain>In addition, HFD-fed Sirt3-KO mice exhibit increased insulin resistance due to defects in skeletal muscle glucose uptake (217). </plain></SENT>
<SENT sid="346" pm="."><plain>These studies suggest that SIRT3 may protect insulin sensitivity in skeletal muscle. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="347" pm="."><plain>SIRT4 </plain></SENT>
</text></title><sec><title><text><SENT sid="348" pm="."><plain>SIRT4 Regulates Lipogenesis </plain></SENT>
</text></title><p><text><SENT sid="349" pm="."><plain>The expression of SIRT4 is upregulated in the liver and adipose tissues in rodents fed an HFD (218, 219). </plain></SENT>
<SENT sid="350" pm="."><plain>SIRT4 deacetylates and inhibits malonyl CoA decarboxylase (MCD), an enzyme producing acetyl-CoA from malonyl CoA, consequently repressing fatty acid oxidation but promoting lipogenesis in WAT and skeletal muscle under nutrient abundance conditions. Sirt4-KO mice display increased exercise tolerance and protection against diet-induced obesity (220). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="351" pm="."><plain>SIRT4 Regulates Fatty Acid Oxidation </plain></SENT>
</text></title><p><text><SENT sid="352" pm="."><plain>SIRT4 inhibition in mouse primary hepatocytes increases fatty acid oxidation gene expression, leading to increased fat oxidative capacity in liver (118). </plain></SENT>
<SENT sid="353" pm="."><plain>The same result is obtained in muscle (118). </plain></SENT>
<SENT sid="354" pm="."><plain>Similarly, primary hepatocytes from Sirt4-KO mice exhibit higher rates of fatty acid oxidation. </plain></SENT>
<SENT sid="355" pm="."><plain>SIRT4 suppresses PPARα activity and inhibits hepatic fatty acid oxidation by modulating SIRT1 activity (221). </plain></SENT>
<SENT sid="356" pm="."><plain>Livers from NAFLD patients exhibit increased SIRT4 and lipogenic gene expression (222). </plain></SENT>
<SENT sid="357" pm="."><plain>These results support the notion that SIRT4 is likely to inhibit fatty acid oxidation and potentiate ectopic lipid storage in liver and skeletal muscle. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="358" pm="."><plain>SIRT5 </plain></SENT>
</text></title><sec><title><text><SENT sid="359" pm="."><plain>SIRT5 in the Regulation of Fatty Acid Metabolism </plain></SENT>
</text></title><p><text><SENT sid="360" pm="."><plain>SIRT5 is highly expressed in metabolic tissues, including the heart, skeletal muscle, brain, liver, and kidney (121). </plain></SENT>
<SENT sid="361" pm="."><plain>Using a label-free quantitative proteomic approach, Rardin et al. characterized the lysine succinylome in liver mitochondria and revealed a major role for SIRT5 in regulating many metabolic pathways, including β-oxidation and ketogenesis (223). </plain></SENT>
<SENT sid="362" pm="."><plain>Park et al. revealed that SIRT5 desuccinylates a set of metabolic enzymes in mitochondria that are involved in amino acid degradation, the TCA cycle and fatty acid metabolism (224). </plain></SENT>
<SENT sid="363" pm="."><plain>In contrast to the other two mitochondrial Sirtuins, SIRT5 protein levels do not change during CR (121, 207). </plain></SENT>
<SENT sid="364" pm="."><plain>However, similar to Sirt3-KO and Sirt4-KO mice, Sirt5-KO mice do not show any overt metabolic abnormalities under either normal chow or HFD conditions (225). </plain></SENT>
<SENT sid="365" pm="."><plain>Sirt5 deficiency does not protect or sensitize mice to the development of HFD-induced obesity, hypertension, and insulin resistance (225). </plain></SENT>
<SENT sid="366" pm="."><plain>The results from Sirt5-KO mice suggest that SIRT5 is not dispensable for cellular metabolism, at least under normal conditions. </plain></SENT>
<SENT sid="367" pm="."><plain>Subsequent studies have shown promising results. </plain></SENT>
<SENT sid="368" pm="."><plain>In humans, SIRT5 gene expression decreases in the liver of NAFLD patients (222), and the expression of SIRT5 in adipose tissue is positively correlated with insulin sensitivity (226). </plain></SENT>
<SENT sid="369" pm="."><plain>Using affinity enrichment and label-free quantitative proteomics, Nishida et al. characterized the SIRT5-regulated lysine malonylome (227). </plain></SENT>
<SENT sid="370" pm="."><plain>Pathway analysis identified gluconeogenesis and glycolysis as the pathways most enriched in SIRT5-regulated malonylated proteins (227). </plain></SENT>
<SENT sid="371" pm="."><plain>SIRT5 regulates glyceraldehyde phosphate dehydrogenase (GAPDH), a glycolytic enzyme, through demalonylation of lysine 184 (227). </plain></SENT>
<SENT sid="372" pm="."><plain>According to these results, SIRT5 may play a critical role in regulating glucose and lipid metabolism and preserving insulin sensitivity. </plain></SENT>
<SENT sid="373" pm="."><plain>Mitochondria-specific Sirtuin knockout mice show no obvious metabolic abnormalities, indicating that mitochondrial Sirtuins serve as nutrient sensors to maintain energy homeostasis. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="374" pm="."><plain>SIRT6 and Insulin-Sensitive Organs </plain></SENT>
</text></title><sec><title><text><SENT sid="375" pm="."><plain>SIRT6 Regulates Adipogenesis, Lipid Metabolism and Thermogenesis in Adipose Tissue </plain></SENT>
</text></title><p><text><SENT sid="376" pm="."><plain>SIRT6 expression is decreased in adipose tissue of db/db mice but increased in adipose tissue of human individuals with weight loss (228, 229), suggesting that SIRT6 plays a role in adipose tissue. </plain></SENT>
<SENT sid="377" pm="."><plain>Chen et al. (230) demonstrated that SIRT6 is required for mitotic clonal expansion during adipogenesis by inhibiting expression of kinesin family member 5C (KIF5C) and subsequent increasing CK2 kinase activity. Sirt6 transgenic mice exhibit resistance to HFD-induced obesity and insulin resistance (231). </plain></SENT>
<SENT sid="378" pm="."><plain>Conversely, fat-specific Sirt6 knockout increases blood glucose levels and hepatic steatosis, and sensitizes mice to HFD-induced obesity and insulin resistance (59, 60, 232). </plain></SENT>
<SENT sid="379" pm="."><plain>SIRT6 overexpression downregulates a set of PPARγ target genes that are involved in lipid metabolism, lipid transport and adipogenesis (231). </plain></SENT>
<SENT sid="380" pm="."><plain>Especially, SIRT6 decreases expressions of ANGPTL4, a negative regulator of lipoprotein lipase, and diglyceride acyltransferase 1 (DGAT1), a key enzyme in triglycerides synthesis, leading to the increased serum triglyceride clearance and reducing triglyceride synthesis in adipose tissues (231). Sirt6 deletion decreases FoxO1 transcriptional activity by increasing its acetylation and phosphorylation and reduces expression of adipose triglyceride lipase (ATGL), a key lipolytic enzyme, reducing lipolysis (59). </plain></SENT>
<SENT sid="381" pm="."><plain>Fat-specific Sirt6 knockout not only induces obesity and insulin resistance but also impairs the thermogenic function of brown adipocytes (232). </plain></SENT>
<SENT sid="382" pm="."><plain>Yao et al. (232) found Sirt6 deletion decreases ATF2 binding to the PGC-1α promoter, leading to reducing the expression of PGC-1α and PGC-1α target thermogenic genes. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="383" pm="."><plain>SIRT6 Represses Gluconeogenesis and Lipid Accumulation in the Liver </plain></SENT>
</text></title><p><text><SENT sid="384" pm="."><plain>The hepatic SIRT6 level is reduced in obese/diabetic mice and gluconeogenic genes were higher in Sirt6-deficient livers whereas ectopic re-expression of SIRT6 suppressed gluconeogenesis and normalizes glycemia (228, 233). </plain></SENT>
<SENT sid="385" pm="."><plain>Mechanistically, SIRT6 interacts with and increases the activity of general control non-repressed protein 5 (GCN5), an acetyltransferase, which, in turn, catalyzes the acetylation of PGC-1α, suppressing gluconeogenic gene expression such as phosphoenolpyruvate carboxykinase C (PEPCK-C) and glucose 6-phosphatase, and resulting in repression of hepatic glucose output (228). </plain></SENT>
<SENT sid="386" pm="."><plain>p53 directly activates expression of SIRT6, which subsequently interacts with and deacetylates FoxO1, leading to FoxO1 export to the cytoplasm, and finally, reduce the expression of gluconeogenetic genes such as glucose 6-phosphatase alpha and phosphoenolpyruvate carboxykinase 1 (234). </plain></SENT>
<SENT sid="387" pm="."><plain>Human fatty liver samples exhibited significantly lower levels of SIRT6 than normal controls and liver-specific deletion of Sirt6 in mice causes increased glycolysis, triglyceride synthesis, reduced β-oxidation, and leads to liver steatosis (235). </plain></SENT>
<SENT sid="388" pm="."><plain>Rosiglitazone, an agonist of PPARγ, increases the expression of SIRT6, PGC-1α, and FoxO1, and AMPK phosphorylation in rat liver and ameliorates hepatic lipid accumulation (236). Sirt6 knockdown abolished the effects of rosiglitazone (236), suggesting Sirt6 at least partly mediates the metabolic effects of rosiglitazone. </plain></SENT>
<SENT sid="389" pm="."><plain>Altogether, those evidence suggest that SIRT6 significantly participates in glucose and lipid metabolism in the liver. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="390" pm="."><plain>SIRT6 Increases Insulin Sensitivity in the Skeletal Muscle </plain></SENT>
</text></title><p><text><SENT sid="391" pm="."><plain>SIRT6 also regulates metabolic homeostasis in the skeletal muscle. Sirt6 transgenic mice show enhanced insulin sensitivity in skeletal muscle and exhibit enhanced insulin-induced activation of Akt in the gastrocnemius (153). </plain></SENT>
<SENT sid="392" pm="."><plain>By contrast, skeletal muscle-specific Sirt6 ko mice exhibit impaired glucose homeostasis and insulin sensitivity, attenuating whole-body energy expenditure (237). </plain></SENT>
<SENT sid="393" pm="."><plain>Mechanistically, Sirt6 deletion decreases AMPK activity and subsequently decreases the expression of genes involved in glucose and lipid uptake, fatty acid oxidation, and mitochondrial oxidative phosphorylation (237). </plain></SENT>
<SENT sid="394" pm="."><plain>Further studies are needed to elucidate the direct mechanism underlying SIRT6 function in skeletal muscle. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="395" pm="."><plain>SIRT7 </plain></SENT>
</text></title><sec><title><text><SENT sid="396" pm="."><plain>SIRT7 Regulates Fatty Acid Metabolism in Adipose Tissues </plain></SENT>
</text></title><p><text><SENT sid="397" pm="."><plain>SIRT7 is the least characterized Sirtuin of the seven mammalian Sirtuins. </plain></SENT>
<SENT sid="398" pm="."><plain>SIRT7 protein levels are high in the liver, spleen, and testis, whereas are low in the muscle, heart, and brain of mice (16). </plain></SENT>
<SENT sid="399" pm="."><plain>In human, Sirt7 mRNA is expressed in various tissues (10). </plain></SENT>
<SENT sid="400" pm="."><plain>Recent reports clarify the important roles of SIRT7 in a variety of biological processes including DNA repair, chromatin assembly, and aging. </plain></SENT>
<SENT sid="401" pm="."><plain>However, the role of SIRT7 in metabolism remains largely unknown. </plain></SENT>
<SENT sid="402" pm="."><plain>The expression of Sirt7 mRNA level is upregulated in adipose tissues of obese patients (238). </plain></SENT>
<SENT sid="403" pm="."><plain>In HFD-fed mice, Sirt7 knockout decreased the expression of the fatty acid transporter CD36 in WAT (239). </plain></SENT>
<SENT sid="404" pm="."><plain>In addition, Sirt7 knockout led to an increase of thermogenesis along with increased expression of UCP1 and DIO2 in BAT (239). </plain></SENT>
<SENT sid="405" pm="."><plain>These results suggest SIRT7 regulates lipid metabolism in adipocytes. </plain></SENT>
<SENT sid="406" pm="."><plain>Recently, Fang al et. found that SIRT7 restricts SIRT1 activity by preventing SIRT1 auto-deacetylation, and increasing SIRT1 activity in Sirt7-KO mice blocks PPARγ and adipocyte differentiation, thereby decreases the accumulation of white fat (240, 241). </plain></SENT>
<SENT sid="407" pm="."><plain>Together, these findings implicate the important role of SIRT7 in the regulation of fatty acid metabolism. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="408" pm="."><plain>SIRT7 Regulates Fatty Acid and Glucose Metabolism in the Liver </plain></SENT>
</text></title><p><text><SENT sid="409" pm="."><plain>Up to now, there are three studies linking SIRT7 to the liver lipid metabolism using independently generated mouse models. </plain></SENT>
<SENT sid="410" pm="."><plain>Shin et al. reported that Sirt7-KO mice developed steatosis resembling human fatty liver disease (242). </plain></SENT>
<SENT sid="411" pm="."><plain>Selectively overexpression of SIRT7 in the liver of Sirt7-KO mice via adeno-associated virus 8 (AAV8)-mediated gene transfer prevents the development of fatty liver (242). </plain></SENT>
<SENT sid="412" pm="."><plain>The authors found expressions of inflammatory markers and lipogenic genes are increased in Sirt7-deficient livers, and they clarified the underlying mechanism as SIRT7 repressing the expression of ribosomal proteins through decreasing Myc activity and further suppressing ER stress (242). </plain></SENT>
<SENT sid="413" pm="."><plain>Ryu et al. generated a different Sirt7-KO mouse by deleting exons 6-9, and observed more general metabolic defects including hepatic microvesicular steatosis, increased blood lactate levels, reduced exercise performance, cardiac dysfunction and age-related hearing loss induced by multisystemic mitochondrial dysfunction (127). </plain></SENT>
<SENT sid="414" pm="."><plain>Mechanistically, SIRT7 deacetylates GABPβ1, thereby enables it to form the transcriptionally active GABPα/GABPβ heterotetramer, and then promotes mitochondria function (127). </plain></SENT>
<SENT sid="415" pm="."><plain>Another study has the opposite result. </plain></SENT>
<SENT sid="416" pm="."><plain>Yoshizawa et al. reported that Sirt7-KO mice, deleting exons 4-9, are resistant to HFD induced fatty liver, obesity, and glucose intolerance (239). </plain></SENT>
<SENT sid="417" pm="."><plain>TR4 is a nuclear receptor involved in lipid metabolism and its target genes increase fatty acid uptake and triglyceride synthesis and storage (243). </plain></SENT>
<SENT sid="418" pm="."><plain>Hepatic SIRT7 was reported to increase TR4 expression through binding with DCAF1/DDB1/CUL4B E3 ubiquitin ligase complex and inhibiting TR4 degradation (239). </plain></SENT>
<SENT sid="419" pm="."><plain>It is difficult to explain the divergence of three Sirt7-KO mouse models with different genetic background. </plain></SENT>
<SENT sid="420" pm="."><plain>Liver-specific knockout or Sirt7 transgene mouse model may be helpful to clarify the role of SIRT7 in liver lipid metabolism (239, 242). </plain></SENT>
<SENT sid="421" pm="."><plain>In addition to lipid metabolism, SIRT7 is involved in glucose metabolism. </plain></SENT>
<SENT sid="422" pm="."><plain>SIRT7 regulates acetylation at the K323 site of phosphoglycerate kinase 1 (PGK1), an important enzyme in glycolysis, decreases PGK1 enzyme activity and inhibits glycolysis in liver cancer cells (244). </plain></SENT>
<SENT sid="423" pm="."><plain>Yoshizawa et al. Found that Sirt7-KO mice show decreased expression of the hepatic glucose-6-phosphatase catalytic subunit (G6PC), a key gluconeogenic enzyme, and resistance to glucose intolerance (239). </plain></SENT>
<SENT sid="425" pm="."><plain>Mechanistically, glucose deprivation stimulates SIRT7 binding to the promoter of G6PC, and deacetylating H3K18 in the G6PC promoter, which results in elevated G6PC expression and promotion of hepatic gluconeogenesis (245). </plain></SENT>
</text></p></sec></sec></sec><sec id="s6"><title><text><SENT sid="426" pm="."><plain>Sirtuins in Aging-related Metabolic Defects </plain></SENT>
</text></title><p><text><SENT sid="427" pm="."><plain>Aging is a complex process accompanied by the declines in basal metabolic rate and physical activity. </plain></SENT>
<SENT sid="428" pm="."><plain>Aging is one of the major risk factors contributing to the development of insulin resistance, obesity, T2DM and metabolic syndrome (246). </plain></SENT>
<SENT sid="429" pm="."><plain>During the aging process, chronic inflammation and mitochondria dysfunction in pancreatic β cells and insulin-sensitive organs have been demonstrated to be major mechanisms linking aging and insulin resistance (247–250). </plain></SENT>
<SENT sid="430" pm="."><plain>As mentioned above, Sirtuins play important roles in regulating inflammation and mitochondria function. </plain></SENT>
<SENT sid="431" pm="."><plain>Sirtuins are critically involved in lifespan and healthspan. </plain></SENT>
<SENT sid="432" pm="."><plain>Deficiency of Sirtuins (SIRT1, SIRT6, and SIRT7) is associated with shortened lifespan and metabolic diseases (251). </plain></SENT>
<SENT sid="433" pm="."><plain>Our recent evidence also demonstrated that SIRT2 deficiency also facilitated the aging-related development of cardiac dysfunction, including hypertrophy and fibrosis (252). </plain></SENT>
<SENT sid="434" pm="."><plain>By contrast, germline or cell-specific overexpression of SIRT1 or SIRT6 were reported to expand lifespan and defense metabolic diseases in insulin-dependent and independent manners (253–255). </plain></SENT>
</text></p><p><text><SENT sid="435" pm="."><plain>Sirtuin-targeted strategies show promising in repressing aging-related insulin resistance and metabolic diseases. </plain></SENT>
<SENT sid="436" pm="."><plain>For instance, the SIRT1 activator SRT1720 extends lifespan and improves the health of mice fed a standard diet (256, 163). </plain></SENT>
<SENT sid="437" pm="."><plain>It is well established that caloric restriction (CR), the Sirtuin activator, is an effective and reliable means to defense against aging and extend the lifespan and healthspan of mammals, including monkeys (257). </plain></SENT>
<SENT sid="438" pm="."><plain>Activation of vascular SIRT1 by CR leads to the repressing of aging-related metabolic vascular diseases, including atherosclerosis and aortic aneurysm (258–260). </plain></SENT>
<SENT sid="439" pm="."><plain>In human studies, CR also can reduce insulin resistance significantly and delay the onset of metabolic diseases (261, 262). </plain></SENT>
<SENT sid="440" pm="."><plain>Although the mechanisms by which CR extend lifespan are not fully understood, Sirtuins have been implicated to mediate beneficial effects of CR on aging (263). </plain></SENT>
<SENT sid="441" pm="."><plain>Notably, the CR mimetics (metformin, resveratrol, rapamycin) could expand lifespan and repress diseases related to insulin resistance in rodents partially through activation of Sirtuins (257, 264). </plain></SENT>
<SENT sid="442" pm="."><plain>Our data showed that SIRT2 contributes to the effects of metformin on aging-related diseases, including cardiac remodeling (252). </plain></SENT>
<SENT sid="443" pm="."><plain>Currently, clinical trials investigating the anti-aging effects of metformin is undergoing (ClinicalTrials.gov Identifier: NCT02432287). </plain></SENT>
</text></p><p><text><SENT sid="444" pm="."><plain>Importantly, the Sirtuins do not function in individual metabolic organs or cell types alone during aging. </plain></SENT>
<SENT sid="445" pm="."><plain>Instead, the Sirtuins orchestrate the crosstalk between different organs or between different cell types within the local microenvironmental niche to maintain metabolic homeostasis and prevent against insulin resistance. </plain></SENT>
<SENT sid="446" pm="."><plain>The SIRT1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression (265). </plain></SENT>
<SENT sid="447" pm="."><plain>Resveratrol activates duodenal SIRT1 to initiate a gut-brain-liver neuronal axis that improves hypothalamic insulin sensitivity in rats (183). </plain></SENT>
<SENT sid="448" pm="."><plain>SIRT1 in intestinal stem cells also contributes to the protection roles of caloric restriction on aging (266). </plain></SENT>
<SENT sid="449" pm="."><plain>In addition, SIRT3 activation by nitrite and metformin improves insulin sensitivity in skeletal muscle and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction (267). </plain></SENT>
<SENT sid="450" pm="."><plain>Sirtuins also regulate inflammatory cells within the local microenvironmental niches to regulate insulin resistance in an autocrine or paracrine manner (41, 79, 80). </plain></SENT>
</text></p><p><text><SENT sid="451" pm="."><plain>Therefore, targeting Sirtuins could be a promising strategy for improvement of insulin sensitivity and metabolic status of the whole body. </plain></SENT>
<SENT sid="452" pm="."><plain>However, activation of Sirtuins alone may not archive the biggest benefits because of the exhaustion of the endogenous NAD. </plain></SENT>
<SENT sid="453" pm="."><plain>Sirtuin activator in supplement with NAD precursor may represent a better therapeutic strategy for repressing aging-related insulin resistance and metabolic diseases. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec id="s7"><title><text><SENT sid="454" pm="."><plain>Concluding Remarks </plain></SENT>
</text></title><p><text><SENT sid="455" pm="."><plain>Insulin resistance is a critical pathological feature of obesity and metabolic syndrome and plays a key role in the pathogenesis of T2DM and attendant cardiovascular complications. </plain></SENT>
<SENT sid="456" pm="."><plain>Moreover, insulin resistance provides a therapeutic strategy to prevent, delay or treat T2DM, obesity, and metabolic syndrome by improving insulin sensitivity. </plain></SENT>
<SENT sid="457" pm="."><plain>Although insulin resistance is a complex metabolic disorder that has remained poorly understood, Sirtuin family members are involved in the potential cellular mechanisms of the pathogenesis of insulin resistance. </plain></SENT>
<SENT sid="458" pm="."><plain>According to accumulating evidence in the past decades, Sirtuin family members have emerged as a nutrient sensor to maintain energy homeostasis. </plain></SENT>
<SENT sid="459" pm="."><plain>Cellular and animal studies have demonstrated that Sirtuins play an important role in regulating glucose and lipids by modulating crucial enzymes in metabolic pathways and interfering with inflammation, oxidative stress, mitochondrial dysfunction, ER stress, and the insulin signaling pathway. </plain></SENT>
</text></p><p><text><SENT sid="460" pm="."><plain>Sirtuins respond to environmental (diet and lifestyle) or metabolic (obesity, fasting, and diabetes) insults at mRNA and protein levels in insulin-sensing organs (268, 269). </plain></SENT>
<SENT sid="461" pm="."><plain>The roles of Sirtuins in regulating glucose and lipid metabolism as well as insulin resistance in liver, adipose tissue, and skeletal muscle make their importance in regulating metabolic diseases, including T2DM and diabetic complications (269). </plain></SENT>
</text></p><p><text><SENT sid="462" pm="."><plain>Nevertheless, many additional studies are needed. </plain></SENT>
</text></p><list list-type="order"><list-item><p><text><SENT sid="463" pm="."><plain>Different Sirtuins may have the same downstream targets, such as FoxO3a, FoxO1, PGC-1α, and GDH, and there is cross-talk among Sirtuin family members (117, 56, 270). </plain></SENT>
<SENT sid="464" pm="?"><plain>How do different Sirtuin members coordinate to regulate the same downstream targets? </plain></SENT>
</text></p></list-item><list-item><p><text><SENT sid="465" pm="."><plain>The Sirtuin family comprises NAD+-dependent histone deacetylases; however, recent results have revealed that Sirtuin members can act in a deacetylase-independent manner (117). </plain></SENT>
<SENT sid="466" pm="?"><plain>How can we determine the functions and activities of Sirtuins in addition to their deacetylation function in insulin resistance? </plain></SENT>
</text></p></list-item><list-item><p><text><SENT sid="467" pm="."><plain>In addition to Sirtuins, there are other epigenetic modification enzymes, including SUV39H1 and EZH2 are involved in insulin resistance and T2DM (271–276). </plain></SENT>
<SENT sid="468" pm="."><plain>There is an interaction between SUV39H1 and Sirtuins, including SIRT1, SIRT3, and SIRT7 (277–281). </plain></SENT>
<SENT sid="469" pm="."><plain>EZH2 is reportedly the deacetylating substrate of SIRT1 (282, 283). </plain></SENT>
<SENT sid="470" pm="."><plain>SIRT2 negatively regulates JMJD2A expression in human non-small cell lung cancer tissues (284). </plain></SENT>
<SENT sid="471" pm="?"><plain>Is JMJD2A involved in insulin resistance? </plain></SENT>
<SENT sid="472" pm="?"><plain>In the condition of insulin resistance, how do these epigenetic modification enzymes influence each other and consequently act on insulin sensitivity? </plain></SENT>
</text></p></list-item><list-item><p><text><SENT sid="473" pm="."><plain>Obesity, insulin resistance, and T2DM are aging-related abnormalities. </plain></SENT>
<SENT sid="474" pm="."><plain>Sirtuins, especially SIRT1, SIRT2, and SIRT6, are characterized as protectors of aging and aging-related diseases. </plain></SENT>
<SENT sid="475" pm="."><plain>Whether the promotive effect of aging by the decline of Sirtuin activity is involved in insulin resistance deserves further investigation. </plain></SENT>
<SENT sid="476" pm="."><plain>In addition, cell senescence-induced organ dysfunction and aging (senescaging) are common during physiological and pathological aging processes (268). </plain></SENT>
<SENT sid="477" pm="."><plain>Selective elimination of senescent cells, or senolysis, was reported to delay aging and aging-related metabolic diseases including congestive decline, atherosclerosis, cardiac diseases, and osteoarthritis (285–291). </plain></SENT>
<SENT sid="478" pm="."><plain>However, it remains to elucidate that what are the physiological and pathological functions of cellular senescence in organs during aging and that whether Sirtuins regulate senescaging in insulin resistance and healthy conditions. </plain></SENT>
</text></p></list-item></list></sec></SecTag><SecTag type="AUTH_CONT"><sec id="s8"><title><text><SENT sid="479" pm="."><plain>Author Contributions </plain></SENT>
</text></title><p><text><SENT sid="480" pm="."><plain>All authors listed have made a substantial, direct and intellectual contribution to the work. </plain></SENT>
<SENT sid="481" pm="."><plain>SZ is responsible for literature collection and article draft. </plain></SENT>
<SENT sid="482" pm="."><plain>XT designed the Figures and revised the manuscript. </plain></SENT>
<SENT sid="483" pm="."><plain>H-ZC is the leading principal investigator who directed the study and data analysis, and prepared the manuscript. </plain></SENT>
<SENT sid="484" pm="."><plain>All authors approved publication of this work. </plain></SENT>
</text></p><sec><title><text><SENT sid="485" pm="."><plain>Conflict of Interest Statement </plain></SENT>
</text></title><p><text><SENT sid="486" pm="."><plain>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="487" pm="."><plain>This work was supported by the National Natural Science Foundation of China (Grant Nos. 81600038, 31571193 and 81800273). </plain></SENT>
<SENT sid="488" pm="."><plain>H-ZC is also supported by the Youth Top-notch Talent Support Program and the Youth Yangtze River Scholar Program in China. </plain></SENT>
<SENT sid="489" pm="."><plain>XT is also supported by the Postdoctoral Innovative Talents Support Program (BX20180206), the China Postdoctoral Science Foundation (2018M631084) and Full-time Postdoctoral Research and Development Fund of Sichuan University (2018SCU12010). </plain></SENT>
<SENT sid="490" pm="."><plain>We apologize to those scientists whose work we could not highlight owing to space limitations. </plain></SENT>
<SENT sid="491" pm="."><plain>We thank Miss. </plain></SENT>
<SENT sid="492" pm="."><plain>Xiao-Feng Chen for reading the manuscript and helpful suggestions. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="493" pm="."><plain>1.SamuelVTShulmanGI. Mechanisms for insulin resistance: common threads and missing links. Cell (2012) 148:852–71. 10.1016/j.cell.2012.02.017<?supplied-pmid 22385956?>22385956 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="494" pm="."><plain>2.SaltielAR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell (2001) 104:517–29. 10.1016/S0092-8674(01)00239-2<?supplied-pmid 11239409?>11239409 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="495" pm="."><plain>3.SunCZhangFGeXYanTChenXShiX. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. (2007) 6:307–19. 10.1016/j.cmet.2007.08.014<?supplied-pmid 17908559?>17908559 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="496" pm="."><plain>4.GomesPFlemingOuteiro TCavadasC. Emerging role of sirtuin 2 in the regulation of mammalian metabolism. Trends Pharmacol Sci. </plain></SENT>
<SENT sid="497" pm="."><plain>(2015) 36:756–68. 10.1016/j.tips.2015.08.001<?supplied-pmid 26538315?>26538315 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="498" pm="."><plain>5.KimJAWeiYSowersJR. Role of mitochondrial dysfunction in insulin resistance. Circul Res. </plain></SENT>
<SENT sid="499" pm="."><plain>(2008) 102:401–14. 10.1161/CIRCRESAHA.107.165472<?supplied-pmid 18309108?>18309108 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="500" pm="."><plain>6.MuoioDMNewgardCB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev. (2008) 9:193–205. 10.1038/nrm2327<?supplied-pmid 18200017?>18200017 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="501" pm="."><plain>7.NogueirasRHabeggerKMChaudharyNFinanBBanksASDietrichMO. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. </plain></SENT>
<SENT sid="502" pm="."><plain>(2012) 92:1479–514. 10.1152/physrev.00022.2011<?supplied-pmid 22811431?>22811431 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="503" pm="."><plain>8.FryeRA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun. </plain></SENT>
<SENT sid="504" pm="."><plain>(1999) 260:273–9. 10.1006/bbrc.1999.0897<?supplied-pmid 10381378?>10381378 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="505" pm="."><plain>9.NorthBJVerdinE. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. </plain></SENT>
<SENT sid="506" pm="."><plain>(2004) 5:224. 10.1186/gb-2004-5-5-224<?supplied-pmid 15128440?>15128440 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="507" pm="."><plain>10.MichishitaEParkJYBurneskisJMBarrettJCHorikawaI. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell (2005) 16:4623–35. 10.1091/mbc.e05-01-0033<?supplied-pmid 16079181?>16079181 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="508" pm="."><plain>11.TannoMSakamotoJMiuraTShimamotoKHorioY. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. </plain></SENT>
<SENT sid="509" pm="."><plain>(2007) 282:6823–32. 10.1074/jbc.M609554200<?supplied-pmid 17197703?>17197703 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="510" pm="."><plain>12.NorthBJMarshallBLBorraMTDenuJMVerdinE. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell (2003) 11:437–44. 10.1016/S1097-2765(03)00038-8<?supplied-pmid 12620231?>12620231 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="511" pm="."><plain>13.VaqueroAScherMBLeeDHSuttonAChengHLAltFW. SIRT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. </plain></SENT>
<SENT sid="512" pm="."><plain>(2006) 20:1256–61. 10.1101/gad.1412706<?supplied-pmid 16648462?>16648462 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="513" pm="."><plain>14.HuangJYHirscheyMDShimazuTHoLVerdinE. Mitochondrial sirtuins. Biochim Biophys Acta (2010) 1804:1645–51. 10.1016/j.bbapap.2009.12.021<?supplied-pmid 20060508?>20060508 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="514" pm="."><plain>15.MostoslavskyRChuaKFLombardDBPangWWFischerMRGellonL. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 124:315–29. 10.1016/j.cell.2005.11.044<?supplied-pmid 16439206?>16439206 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="515" pm="."><plain>16.FordEVoitRLisztGMaginCGrummtIGuarenteL. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. </plain></SENT>
<SENT sid="516" pm="."><plain>(2006) 20:1075–80. 10.1101/gad.1399706<?supplied-pmid 16618798?>16618798 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="517" pm="."><plain>17.RauhDFischerFGertzMLakshminarasimhanMBergbredeTAladiniF. An acetylome peptide microarray reveals specificities and deacetylation substrates for all human sirtuin isoforms. Nat Commun. </plain></SENT>
<SENT sid="518" pm="."><plain>(2013) 4:2327. 10.1038/ncomms3327<?supplied-pmid 23995836?>23995836 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="519" pm="."><plain>18.TengYBJingHAramsangtienchaiPHeBKhanSHuJ. Efficient demyristoylase activity of SIRT2 revealed by kinetic and structural studies. Sci Rep. </plain></SENT>
<SENT sid="520" pm="."><plain>(2015) 5:8529. 10.1038/srep08529<?supplied-pmid 25704306?>25704306 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="521" pm="."><plain>19.DuJZhouYSuXYuJJKhanSJiangH. SIRT5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science (2011) 334:806–9. 10.1126/science.1207861<?supplied-pmid 22076378?>22076378 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="522" pm="."><plain>20.HaigisMCMostoslavskyRHaigisKMFahieKChristodoulouDCMurphyAJ. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell (2006) 126:941–54. 10.1016/j.cell.2006.06.057<?supplied-pmid 16959573?>16959573 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="523" pm="."><plain>21.LisztGFordEKurtevMGuarenteL. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem. </plain></SENT>
<SENT sid="524" pm="."><plain>(2005) 280:21313–20. 10.1074/jbc.M413296200<?supplied-pmid 15795229?>15795229 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="525" pm="."><plain>22.GuarenteLFranklinH. Epstein lecture: sirtuins, aging, and medicine. N Engl J Med. </plain></SENT>
<SENT sid="526" pm="."><plain>(2011) 364:2235–44. 10.1056/NEJMra1100831<?supplied-pmid 21651395?>21651395 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="527" pm="."><plain>23.MorrisBJ. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med. </plain></SENT>
<SENT sid="528" pm="."><plain>(2013) 56:133–71. 10.1016/j.freeradbiomed.2012.10.525<?supplied-pmid 23104101?>23104101 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="529" pm="."><plain>24.LiangFKumeSKoyaD. SIRT1 and insulin resistance. Nat Rev. </plain></SENT>
<SENT sid="530" pm="."><plain>Endocrinol. </plain></SENT>
<SENT sid="531" pm="."><plain>(2009) 5:367–73. 10.1038/nrendo.2009.101<?supplied-pmid 19455179?>19455179 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="532" pm="."><plain>25.CaoYJiangXMaHWangYXuePLiuY. SIRT1 and insulin resistance. J Diabetes Compl. </plain></SENT>
<SENT sid="533" pm="."><plain>(2016) 30:178–83. 10.1016/j.jdiacomp.2015.08.022<?supplied-pmid 26422395?>26422395 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="534" pm="."><plain>26.KuangJChenLTangQZhangJLiYHeJ. The role of SIRT6 in obesity and diabetes. Front Physiol. </plain></SENT>
<SENT sid="535" pm="."><plain>(2018) 9:135. 10.3389/fphys.2018.00135<?supplied-pmid 29535637?>29535637 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="536" pm="."><plain>27.WellenKEHotamisligilGS. Inflammation, stress, and diabetes. J Clin Investig. </plain></SENT>
<SENT sid="537" pm="."><plain>(2005) 115:1111–9. 10.1172/JCI25102<?supplied-pmid 15864338?>15864338 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="538" pm="."><plain>28.OlefskyJMGlassCK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. </plain></SENT>
<SENT sid="539" pm="."><plain>(2010) 72:219–46. 10.1146/annurev-physiol-021909-135846<?supplied-pmid 20148674?>20148674 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="540" pm="."><plain>29.LumengCNSaltielAR. Inflammatory links between obesity and metabolic disease. J Clin Investig. </plain></SENT>
<SENT sid="541" pm="."><plain>(2011) 121:2111–7. 10.1172/JCI57132<?supplied-pmid 21633179?>21633179 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="542" pm="."><plain>30.SchererPE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes (2006) 55:1537–45. 10.2337/db06-0263<?supplied-pmid 16731815?>16731815 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="543" pm="."><plain>31.WangPMarimanERenesJKeijerJ. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol. </plain></SENT>
<SENT sid="544" pm="."><plain>(2008) 216:3–13. 10.1002/jcp.21386<?supplied-pmid 18264975?>18264975 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="545" pm="."><plain>32.SteppanCMBaileySTBhatSBrownEJBanerjeeRRWrightCM. The hormone resistin links obesity to diabetes. Nature (2001) 409:307–12. 10.1038/35053000<?supplied-pmid 11201732?>11201732 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="546" pm="."><plain>33.YangQGrahamTEModyNPreitnerFPeroniODZabolotnyJM. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature (2005) 436:356–62. 10.1038/nature03711<?supplied-pmid 16034410?>16034410 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="547" pm="."><plain>34.HirosumiJTuncmanGChangLGorgunCZUysalKTMaedaK. A central role for JNK in obesity and insulin resistance. Nature (2002) 420:333–6. 10.1038/nature01137<?supplied-pmid 12447443?>12447443 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="548" pm="."><plain>35.ZickY. Role of Ser/Thr kinases in the uncoupling of insulin signaling. Int J Obes Related Metab Disord. (2003) 27(Suppl. </plain></SENT>
<SENT sid="549" pm="."><plain>3):S56–60. 10.1038/sj.ijo.0802503<?supplied-pmid 14704747?>14704747 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="550" pm="."><plain>36.JingEEmanuelliBHirscheyMDBoucherJLeeKYLombardD. Sirtuin-3 (SIRT3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci USA (2011) 108:14608–13. 10.1073/pnas.1111308108<?supplied-pmid 21873205?>21873205 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="551" pm="."><plain>37.PflugerPTHerranzDVelasco-MiguelSSerranoMTschopMH. SIRT1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA (2008) 105:9793–8. 10.1073/pnas.0802917105<?supplied-pmid 18599449?>18599449 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="552" pm="."><plain>38.PurushothamASchugTTXuQSurapureddiSGuoXLiX. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. </plain></SENT>
<SENT sid="553" pm="."><plain>(2009) 9:327–38. 10.1016/j.cmet.2009.02.006<?supplied-pmid 19356714?>19356714 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="554" pm="."><plain>39.YoshizakiTMilneJCImamuraTSchenkSSonodaNBabendureJL. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol. </plain></SENT>
<SENT sid="555" pm="."><plain>(2009) 29:1363–74. 10.1128/MCB.00705-08<?supplied-pmid 19103747?>19103747 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="556" pm="."><plain>40.YoshizakiTSchenkSImamuraTBabendureJLSonodaNBaeEJ. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol. </plain></SENT>
<SENT sid="557" pm="."><plain>Endocrinol Metab. </plain></SENT>
<SENT sid="558" pm="."><plain>(2010) 298:E419–428. 10.1152/ajpendo.00417.2009<?supplied-pmid 19996381?>19996381 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="559" pm="."><plain>41.GillumMPKotasMEErionDMKursaweRChatterjeePNeadKT. SIRT1 regulates adipose tissue inflammation. Diabetes (2011) 60:3235–45. 10.2337/db11-0616<?supplied-pmid 22110092?>22110092 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="560" pm="."><plain>42.HuiXZhangMGuPLiKGaoYWuD. Adipocyte SIRT1 controls systemic insulin sensitivity by modulating macrophages in adipose tissue. EMBO Rep. </plain></SENT>
<SENT sid="561" pm="."><plain>(2017) 18:645–57. 10.15252/embr.201643184<?supplied-pmid 28270525?>28270525 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="562" pm="."><plain>43.YeungFHobergJERamseyCSKellerMDJonesDRFryeRA. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. (2004) 23:2369–80. 10.1038/sj.emboj.7600244<?supplied-pmid 15152190?>15152190 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="564" pm="."><plain>44.GhoshHSSpencerJVNgBMcBurneyMWRobbinsPD. SIRT1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor kappaB-mediated transcription. Biochem J. (2007) 408:105–111. 10.1042/BJ20070817<?supplied-pmid 17680780?>17680780 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="566" pm="."><plain>45.ZhangRChenHZLiuJJJiaYYZhangZQYangRF. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem. </plain></SENT>
<SENT sid="567" pm="."><plain>(2010) 285:7097–110. 10.1074/jbc.M109.038604<?supplied-pmid 20042607?>20042607 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="568" pm="."><plain>46.NakamuraKZhangMKageyamaSKeBFujiiTSosaRA. Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury. J Hepatol. </plain></SENT>
<SENT sid="569" pm="."><plain>(2017) 67:1232–42. 10.1016/j.jhep.2017.08.010<?supplied-pmid 28842295?>28842295 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="570" pm="."><plain>47.RothgiesserKMErenerSWaibelSLuscherBHottigerMO. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci. </plain></SENT>
<SENT sid="571" pm="."><plain>(2010) 123:4251–8. 10.1242/jcs.073783<?supplied-pmid 21081649?>21081649 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="572" pm="."><plain>48.PaisTFSzegoEMMarquesOMiller-FlemingLAntasPGuerreiroP. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J. (2013) 32:2603–16. 10.1038/emboj.2013.200<?supplied-pmid 24013120?>24013120 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="574" pm="."><plain>49.LoSasso GMenziesKJMottisAPiersigilliAPerinoAYamamotoH SIRT2 deficiency modulates macrophage polarization and susceptibility to experimental colitis. PLoS ONE (2014) 9:e103573 10.1371/journal.pone.010357325072851 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="575" pm="."><plain>50.ZhangYChiD. Overexpression of SIRT2 alleviates neuropathic pain and neuroinflammation through deacetylation of transcription factor nuclear factor-kappa B. Inflammation (2018) 41:569–78. 10.1007/s10753-017-0713-3<?supplied-pmid 29222643?>29222643 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="576" pm="."><plain>51.YuanFXuZMLuLYNieHDingJYingWH. SIRT2 inhibition exacerbates neuroinflammation and blood–brain barrier disruption in experimental traumatic brain injury by enhancing NF-κB p65 acetylation and activation. J Neurochem. </plain></SENT>
<SENT sid="577" pm="."><plain>(2016) 136:581–93. 10.1111/jnc.13423<?supplied-pmid 26546505?>26546505 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="578" pm="."><plain>52.LinJSunBJiangCHongHZhengY. SIRT2 suppresses inflammatory responses in collagen-induced arthritis. Biochem Biophys Res Commun. </plain></SENT>
<SENT sid="579" pm="."><plain>(2013) 441:897–903. 10.1016/j.bbrc.2013.10.153<?supplied-pmid 24211200?>24211200 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="580" pm="."><plain>53.WangXBuechlerNLMartinAWellsJYozaBMcCallCE Sirtuin-2 regulates sepsis inflammation in ob/ob mice. PLoS ONE (2016) 11:e0160431 10.1371/journal.pone.016043127500833 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="581" pm="."><plain>54.ChenYWangHLuoGDaiX. SIRT4 inhibits cigarette smoke extracts-induced mononuclear cell adhesion to human pulmonary microvascular endothelial cells via regulating NF-kappaB activity. Toxicol Lett. </plain></SENT>
<SENT sid="582" pm="."><plain>(2014) 226:320–7. 10.1016/j.toxlet.2014.02.022<?supplied-pmid 24603126?>24603126 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="583" pm="."><plain>55.TaoYHuangCHuangYHongLWangHZhouZ. SIRT4 suppresses inflammatory responses in human umbilical vein endothelial cells. Cardiovasc Toxicol. </plain></SENT>
<SENT sid="584" pm="."><plain>(2015) 15:217–23. 10.1007/s12012-014-9287-6<?supplied-pmid 25331589?>25331589 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="585" pm="."><plain>56.QinKHanCZhangHLiTLiNCaoX. NAD(+) dependent deacetylase Sirtuin 5 rescues the innate inflammatory response of endotoxin tolerant macrophages by promoting acetylation of p65. J Autoimmun. </plain></SENT>
<SENT sid="586" pm="."><plain>(2017) 81:120–9. 10.1016/j.jaut.2017.04.006<?supplied-pmid 28461090?>28461090 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="587" pm="."><plain>57.WangFWangKXuWZhaoSYeDWangY. SIRT5 desuccinylates and activates pyruvate kinase M2 to block macrophage IL-1beta production and to prevent DSS-induced colitis in mice. Cell Rep. </plain></SENT>
<SENT sid="588" pm="."><plain>(2017) 19:2331–44. 10.1016/j.celrep.2017.05.065<?supplied-pmid 28614718?>28614718 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="589" pm="."><plain>58.KawaharaTLMichishitaEAdlerASDamianMBerberELinM. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell (2009) 136:62–74. 10.1016/j.cell.2008.10.052<?supplied-pmid 19135889?>19135889 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="590" pm="."><plain>59.KuangJZhangYLiuQShenJPuSChengS. Fat-specific SIRT6 ablation sensitizes mice to high-fat diet-induced obesity and insulin resistance by inhibiting lipolysis. Diabetes (2017) 66:1159–71. 10.2337/db16-1225<?supplied-pmid 28250020?>28250020 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="591" pm="."><plain>60.XiongXZhangCZhangYFanRQianXDongXC. Fabp4-Cre-mediated SIRT6 deletion impairs adipose tissue function and metabolic homeostasis in mice. J Endocrinol. </plain></SENT>
<SENT sid="592" pm="."><plain>(2017) 233:307–14. 10.1530/JOE-17-0033<?supplied-pmid 28385723?>28385723 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="593" pm="."><plain>61.FranchiLEigenbrodTMunoz-PlanilloRNunezG. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. </plain></SENT>
<SENT sid="594" pm="."><plain>(2009) 10:241–7. 10.1038/ni.1703<?supplied-pmid 19221555?>19221555 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="595" pm="."><plain>62.LamkanfiMDixitVM. Mechanisms and functions of inflammasomes. Cell (2014) 157:1013–22. 10.1016/j.cell.2014.04.007<?supplied-pmid 24855941?>24855941 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="596" pm="."><plain>63.YoumYHNguyenKYGrantRWGoldbergELBodogaiMKimD. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. </plain></SENT>
<SENT sid="597" pm="."><plain>(2015) 21:263–9. 10.1038/nm.3804<?supplied-pmid 25686106?>25686106 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="598" pm="."><plain>64.VandanmagsarBYoumYHRavussinAGalganiJEStadlerKMynattRL. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. </plain></SENT>
<SENT sid="599" pm="."><plain>(2011) 17:179–88. 10.1038/nm.2279<?supplied-pmid 21217695?>21217695 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="600" pm="."><plain>65.LeeHMKimJJKimHJShongMKuBJJoEK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes (2013) 62:194–204. 10.2337/db12-0420<?supplied-pmid 23086037?>23086037 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="601" pm="."><plain>66.FuYWangYDuLXuCCaoJFanT. Resveratrol inhibits ionising irradiation-induced inflammation in MSCs by activating SIRT1 and limiting NLRP-3 inflammasome activation. Int J Mol Sci. </plain></SENT>
<SENT sid="602" pm="."><plain>(2013) 14:14105–18. 10.3390/ijms140714105<?supplied-pmid 23880858?>23880858 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="603" pm="."><plain>67.GaoRMaZHuYChenJShettySFuJ. SIRT1 restrains lung inflammasome activation in a murine model of sepsis. Am J Physiol. </plain></SENT>
<SENT sid="604" pm="."><plain>(2015) 308:L847–853. 10.1152/ajplung.00274.2014<?supplied-pmid 25659903?>25659903 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="605" pm="."><plain>68.ZhangBXuDSheLWangZYangNSunR. Silybin inhibits NLRP3 inflammasome assembly through the NAD(+)/SIRT2 pathway in mice with nonalcoholic fatty liver disease. FASEB J. (2018) 32:757–67. 10.1096/fj.201700602R<?supplied-pmid 28970254?>28970254 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="607" pm="."><plain>69.TrabaJKwarteng-SiawMOkoliTCLiJHuffstutlerRDBrayA. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J Clin Investig. </plain></SENT>
<SENT sid="608" pm="."><plain>(2015) 125:4592–600. 10.1172/JCI83260<?supplied-pmid 26529255?>26529255 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="609" pm="."><plain>70.ChenMLZhuXHLangHDMiMT. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J Am Heart Assoc. </plain></SENT>
<SENT sid="610" pm="."><plain>(2017) 6:e006347. 10.1161/JAHA.117.006347<?supplied-pmid 28871042?>28871042 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="611" pm="."><plain>71.HarrisJHartmanMRocheCZengSGO'SheaASharpFA. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem. </plain></SENT>
<SENT sid="612" pm="."><plain>(2011) 286:9587–97. 10.1074/jbc.M110.202911<?supplied-pmid 21228274?>21228274 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="613" pm="."><plain>72.ChenYLiXBoiniKMPitzerALGulbinsEZhangY. Endothelial Nlrp3 inflammasome activation associated with lysosomal destabilization during coronary arteritis. Biochim Biophys Acta (2015) 1853:396–408. 10.1016/j.bbamcr.2014.11.012<?supplied-pmid 25450976?>25450976 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="614" pm="."><plain>73.LiuPHuangGWeiTGaoJHuangCSunM. Sirtuin 3-induced macrophage autophagy in regulating NLRP3 inflammasome activation. Biochim Biophys Acta (2018) 1864:764–77. 10.1016/j.bbadis.2017.12.027<?supplied-pmid 29277324?>29277324 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="615" pm="."><plain>74.NakahiraKHaspelJARathinamVALeeSJDolinayTLamHC. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. </plain></SENT>
<SENT sid="616" pm="."><plain>(2011) 12:222–230. 10.1038/ni.1980<?supplied-pmid 21151103?>21151103 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="617" pm="."><plain>75.ChoKWLumengCN. SIRT1: a guardian at the gates of adipose tissue inflammation. Diabetes (2011) 60:3100–2. 10.2337/db11-1308<?supplied-pmid 22110091?>22110091 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="618" pm="."><plain>76.ZhangJLeeSMShannonSGaoBChenWChenA. The type III histone deacetylase SIRT1 is essential for maintenance of T cell tolerance in mice. J Clin Invest. </plain></SENT>
<SENT sid="619" pm="."><plain>(2009) 119:3048–58. 10.1172/JCI38902<?supplied-pmid 19729833?>19729833 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="620" pm="."><plain>77.LiuZGanLLiuGChenYWuTFengF. SIRT1 decreased adipose inflammation by interacting with Akt2 and inhibiting mTOR/S6K1 pathway in mice. J Lipid Res. (2016) 57:1373–81. 10.1194/jlr.M063537<?supplied-pmid 27317762?>27317762 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="621" pm="."><plain>78.JiangHKhanSWangYCharronGHeBSebastianC. SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine. Nature (2013) 496:110–3. 10.1038/nature12038<?supplied-pmid 23552949?>23552949 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="622" pm="."><plain>79.LeeYKaSOChaHNChaeYNKimMKParkSY. Myeloid sirtuin 6 deficiency causes insulin resistance in high-fat diet–fed mice by eliciting macrophage polarization toward an m1 phenotype. Diabetes (2017) 66:2659–68. 10.2337/db16-1446<?supplied-pmid 28607107?>28607107 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="623" pm="."><plain>80.ZhangZQRenSCTanYLiZZTangXWangTT. Epigenetic regulation of NKG2D ligands is involved in exacerbated atherosclerosis development in SIRT6 heterozygous mice. Sci Rep. </plain></SENT>
<SENT sid="624" pm="."><plain>(2016) 6:23912. 10.1038/srep23912<?supplied-pmid 27045575?>27045575 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="625" pm="."><plain>81.XiaoCWangRHLahusenTJParkOBertolaAMaruyamaT. Progression of chronic liver inflammation and fibrosis driven by activation of c-JUN signaling in SIRT6 mutant mice. J Biol Chem. (2012) 287:41903–13. 10.1074/jbc.M112.415182<?supplied-pmid 23076146?>23076146 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="626" pm="."><plain>82.LiuTFVachharajaniVTYozaBKMcCallCE. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J Biol Chem. (2012) 287:25758–69. 10.1074/jbc.M112.362343<?supplied-pmid 22700961?>22700961 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="627" pm="."><plain>83.Pham-HuyLAHeHPham-HuyC. Free radicals, antioxidants in disease and health. Int J Biomed Sci. (2008) 4:89–96. <?supplied-pmid 23675073?>23675073 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="628" pm="."><plain>84.SinghCKChhabraGNdiayeMAGarcia-PetersonLMMackNJAhmadN. The role of sirtuins in antioxidant and redox signaling. Antiox Redox Signal. </plain></SENT>
<SENT sid="629" pm="."><plain>(2018) 28:643–61. 10.1089/ars.2017.7290<?supplied-pmid 28891317?>28891317 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="630" pm="."><plain>85.MaieseK. New insights for oxidative stress and diabetes mellitus. Oxidat Med Cell Long. </plain></SENT>
<SENT sid="631" pm="."><plain>(2015) 2015:875961. 10.1155/2015/875961<?supplied-pmid 26064426?>26064426 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="632" pm="."><plain>86.KelleyDEHeJMenshikovaEVRitovVB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes (2002) 51:2944–50. 10.2337/diabetes.51.10.2944<?supplied-pmid 12351431?>12351431 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="633" pm="."><plain>87.PetersenKFDufourSBefroyDGarciaRShulmanGI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. </plain></SENT>
<SENT sid="634" pm="."><plain>(2004) 350:664–71. 10.1056/NEJMoa031314<?supplied-pmid 14960743?>14960743 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="635" pm="."><plain>88.LowellBBShulmanGI. Mitochondrial dysfunction and type 2 diabetes. Science (2005) 307:384–7. 10.1126/science.1104343<?supplied-pmid 15662004?>15662004 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="636" pm="."><plain>89.WuZPuigserverPAnderssonUZhangCAdelmantGMoothaV. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 98:115–24. 10.1016/S0092-8674(00)80611-X<?supplied-pmid 10412986?>10412986 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="637" pm="."><plain>90.FinckBNKellyDP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Investig. </plain></SENT>
<SENT sid="638" pm="."><plain>(2006) 116:615–22. 10.1172/JCI27794<?supplied-pmid 16511594?>16511594 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="639" pm="."><plain>91.NemotoSFergussonMMFinkelT. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem. </plain></SENT>
<SENT sid="640" pm="."><plain>(2005) 280:16456–60. 10.1074/jbc.M501485200<?supplied-pmid 15716268?>15716268 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="641" pm="."><plain>92.LagougeMArgmannCGerhart-HinesZMezianeHLerinCDaussinF. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell (2006) 127:1109–22. 10.1016/j.cell.2006.11.013<?supplied-pmid 17112576?>17112576 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="642" pm="."><plain>93.LeeIHCaoLMostoslavskyRLombardDBLiuJBrunsNE. A role for the NAD-dependent deacetylase SIRT1 in the regulation of autophagy. Proc Natl Acad Sci USA (2008) 105:3374–9. 10.1073/pnas.0712145105<?supplied-pmid 18296641?>18296641 </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="643" pm="."><plain>94.HariharanNMaejimaYNakaeJPaikJDepinhoRASadoshimaJ Deacetylation of FoxO by SIRT1 Plays an Essential Role in Mediating Starvation-Induced Autophagy in Cardiac Myocytes, Circ Res. </plain></SENT>
<SENT sid="644" pm="."><plain>(2010) 107:1470–82. 10.1161/CIRCRESAHA.110.227371 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="645" pm="."><plain>95.KumeSUzuTHoriikeKChin-KanasakiMIsshikiKArakiS. Calorie restriction enhances cell adaptation to hypoxia through SIRT1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Investig. </plain></SENT>
<SENT sid="646" pm="."><plain>(2010) 120:1043–55. 10.1172/JCI41376<?supplied-pmid 20335657?>20335657 </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="647" pm="."><plain>96.BrunetASweeneyLBSturgillJFChuaKFGreerPLLinY. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (2004) 303:2011–15. 10.1126/science.1094637<?supplied-pmid 14976264?>14976264 </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="648" pm="."><plain>97.ZhangBZhaiMLiBLiuZLiKJiangL. Honokiol ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by reducing oxidative stress and apoptosis through activating the SIRT1-Nrf2 signaling pathway. Oxidat Med Cell Long. </plain></SENT>
<SENT sid="649" pm="."><plain>(2018) 2018:3159801. 10.1155/2018/3159801<?supplied-pmid 29675132?>29675132 </plain></SENT>
</text></ref><ref id="B98"><text><SENT sid="650" pm="."><plain>98.WangFNguyenMQinFXTongQ. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell (2007) 6:505–14. 10.1111/j.1474-9726.2007.00304.x<?supplied-pmid 17521387?>17521387 </plain></SENT>
</text></ref><ref id="B99"><text><SENT sid="651" pm="."><plain>99.LynnEGMcLeodCJGordonJPBaoJSackMN. SIRT2 is a negative regulator of anoxia-reoxygenation tolerance via regulation of 14-3-3 zeta and BAD in H9c2 cells. FEBS Lett. </plain></SENT>
<SENT sid="652" pm="."><plain>(2008) 582:2857–62. 10.1016/j.febslet.2008.07.016<?supplied-pmid 18640115?>18640115 </plain></SENT>
</text></ref><ref id="B100"><text><SENT sid="653" pm="."><plain>100.WangYPZhouLSZhaoYZWangSWChenLLLiuLX. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. (2014) 33:1304–20. 10.1002/embj.201387224<?supplied-pmid 24769394?>24769394 </plain></SENT>
</text></ref><ref id="B101"><text><SENT sid="655" pm="."><plain>101.XuYLiFLvLLiTZhouXDengCX. Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res. </plain></SENT>
<SENT sid="656" pm="."><plain>(2014) 74:3630–42. 10.1158/0008-5472.CAN-13-3615<?supplied-pmid 24786789?>24786789 </plain></SENT>
</text></ref><ref id="B102"><text><SENT sid="657" pm="."><plain>102.GalliganJJRoseKLBeaversWNHillSTallmanKATanseyWP. Stable histone adduction by 4-oxo-2-nonenal: a potential link between oxidative stress and epigenetics. J Am Chem Soc. </plain></SENT>
<SENT sid="658" pm="."><plain>(2014) 136:11864–6. 10.1021/ja503604t<?supplied-pmid 25099620?>25099620 </plain></SENT>
</text></ref><ref id="B103"><text><SENT sid="659" pm="."><plain>103.JinJHeBZhangXLinHWangY. SIRT2 reverses 4-oxononanoyl lysine modification on histones. J Am Chem Soc. </plain></SENT>
<SENT sid="660" pm="."><plain>(2016) 138:12304–7. 10.1021/jacs.6b04977<?supplied-pmid 27610633?>27610633 </plain></SENT>
</text></ref><ref id="B104"><text><SENT sid="661" pm="."><plain>104.LiuGParkSHImbesiMNathanWJZouXZhuY. Loss of NAD-dependent protein deacetylase sirtuin-2 alters mitochondrial protein acetylation and dysregulates mitophagy. Antioxid Redox Signal. </plain></SENT>
<SENT sid="662" pm="."><plain>(2017) 26:849–63. 10.1089/ars.2016.6662<?supplied-pmid 27460777?>27460777 </plain></SENT>
</text></ref><ref id="B105"><text><SENT sid="663" pm="."><plain>105.WeirHJLaneJDBalthasarN. SIRT3: a central regulator of mitochondrial adaptation in health and disease. Genes Cancer (2013) 4:118–24. 10.1177/1947601913476949<?supplied-pmid 24020003?>24020003 </plain></SENT>
</text></ref><ref id="B106"><text><SENT sid="664" pm="."><plain>106.AhnBHKimHSSongSLeeIHLiuJVassilopoulosA. A role for the mitochondrial deacetylase SIRT3 in regulating energy homeostasis. Proc Natl Acad Sci USA (2008) 105:14447–52. 10.1073/pnas.0803790105<?supplied-pmid 18794531?>18794531 </plain></SENT>
</text></ref><ref id="B107"><text><SENT sid="665" pm="."><plain>107.CimenHHanMJYangYTongQKocHKocEC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry (2010) 49:304–11. 10.1021/bi901627u<?supplied-pmid 20000467?>20000467 </plain></SENT>
</text></ref><ref id="B108"><text><SENT sid="666" pm="."><plain>108.HafnerAVDaiJGomesAPXiaoCYPalmeiraCMRosenzweigA. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (2010) 2:914–23. 10.18632/aging.100252<?supplied-pmid 21212461?>21212461 </plain></SENT>
</text></ref><ref id="B109"><text><SENT sid="667" pm="."><plain>109.ChengYRenXGowdaASShanYZhangLYuanYS. Interaction of SIRT3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis. </plain></SENT>
<SENT sid="668" pm="."><plain>(2013) 4:e731. 10.1038/cddis.2013.254<?supplied-pmid 23868064?>23868064 </plain></SENT>
</text></ref><ref id="B110"><text><SENT sid="669" pm="."><plain>110.SomeyaSYuWHallowsWCXuJVannJMLeeuwenburghC. SIRT3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell (2010) 143:802–12. 10.1016/j.cell.2010.10.002<?supplied-pmid 21094524?>21094524 </plain></SENT>
</text></ref><ref id="B111"><text><SENT sid="670" pm="."><plain>111.FinleyLWCarracedoALeeJSouzaAEgiaAZhangJ. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell (2011) 19:416–28. 10.1016/j.ccr.2011.02.014<?supplied-pmid 21397863?>21397863 </plain></SENT>
</text></ref><ref id="B112"><text><SENT sid="671" pm="."><plain>112.SundaresanNRGuptaMKimGRajamohanSBIsbatanAGuptaMP. SIRT3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Investig. </plain></SENT>
<SENT sid="672" pm="."><plain>(2009) 119:2758–71. 10.1172/JCI39162<?supplied-pmid 19652361?>19652361 </plain></SENT>
</text></ref><ref id="B113"><text><SENT sid="673" pm="."><plain>113.QiuXBrownKHirscheyMDVerdinEChenD. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. </plain></SENT>
<SENT sid="674" pm="."><plain>(2010) 12:662–7. 10.1016/j.cmet.2010.11.015<?supplied-pmid 21109198?>21109198 </plain></SENT>
</text></ref><ref id="B114"><text><SENT sid="675" pm="."><plain>114.ChenYZhangJLinYLeiQGuanKLZhaoS. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. </plain></SENT>
<SENT sid="676" pm="."><plain>(2011) 12:534–41. 10.1038/embor.2011.65<?supplied-pmid 21566644?>21566644 </plain></SENT>
</text></ref><ref id="B115"><text><SENT sid="677" pm="."><plain>115.TaoRColemanMCPenningtonJDOzdenOParkSHJiangH. SIRT3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell (2010) 40:893–904. 10.1016/j.molcel.2010.12.013<?supplied-pmid 21172655?>21172655 </plain></SENT>
</text></ref><ref id="B116"><text><SENT sid="678" pm="."><plain>116.YuWDittenhafer-ReedKEDenuJM. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol Chem. </plain></SENT>
<SENT sid="679" pm="."><plain>(2012) 287:14078–86. 10.1074/jbc.M112.355206<?supplied-pmid 22416140?>22416140 </plain></SENT>
</text></ref><ref id="B117"><text><SENT sid="680" pm="."><plain>117.LuoYXTangXAnXZXieXMChenXFZhaoX. SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur Heart J. (2017) 38:1389–98. 10.1093/eurheartj/ehw138<?supplied-pmid 27099261?>27099261 </plain></SENT>
</text></ref><ref id="B118"><text><SENT sid="681" pm="."><plain>118.NasrinNWuXFortierEFengYBareOCChenS. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem. </plain></SENT>
<SENT sid="682" pm="."><plain>(2010) 285:31995–2002. 10.1074/jbc.M110.124164<?supplied-pmid 20685656?>20685656 </plain></SENT>
</text></ref><ref id="B119"><text><SENT sid="683" pm="."><plain>119.HoLTitusASBanerjeeKKGeorgeSLinWDeotaS. SIRT4 regulates ATP homeostasis and mediates a retrograde signaling via AMPK. Aging (2013) 5:835–49. 10.18632/aging.100616<?supplied-pmid 24296486?>24296486 </plain></SENT>
</text></ref><ref id="B120"><text><SENT sid="684" pm="."><plain>120.LangAAnandRAltinoluk-HambuchenSEzzahoiniHStefanskiAIramA. SIRT4 interacts with OPA1 and regulates mitochondrial quality control and mitophagy. Aging (2017) 9:2163–89. 10.18632/aging.101307<?supplied-pmid 29081403?>29081403 </plain></SENT>
</text></ref><ref id="B121"><text><SENT sid="685" pm="."><plain>121.NakagawaTLombDJHaigisMCGuarenteL. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell (2009) 137:560–70. 10.1016/j.cell.2009.02.026<?supplied-pmid 19410549?>19410549 </plain></SENT>
</text></ref><ref id="B122"><text><SENT sid="686" pm="."><plain>122.LinZFXuHBWangJYLinQRuanZLiuFB. SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem Biophys Res Commun. </plain></SENT>
<SENT sid="687" pm="."><plain>(2013) 441:191–5. 10.1016/j.bbrc.2013.10.033<?supplied-pmid 24140062?>24140062 </plain></SENT>
</text></ref><ref id="B123"><text><SENT sid="688" pm="."><plain>123.ZhouLWangFSunRChenXZhangMXuQ. SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense. EMBO Rep. </plain></SENT>
<SENT sid="689" pm="."><plain>(2016) 17:811–22. 10.15252/embr.201541643<?supplied-pmid 27113762?>27113762 </plain></SENT>
</text></ref><ref id="B124"><text><SENT sid="690" pm="."><plain>124.ChenXFTianMXSunRQZhangMLZhouLSJinL. SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep. </plain></SENT>
<SENT sid="691" pm="."><plain>(2018) 19:e45124. 10.15252/embr.201745124<?supplied-pmid 29491006?>29491006 </plain></SENT>
</text></ref><ref id="B125"><text><SENT sid="692" pm="."><plain>125.PanHGuanDLiuXLiJWangLWuJ. SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. Cell Res. </plain></SENT>
<SENT sid="693" pm="."><plain>(2016) 26:190–205. 10.1038/cr.2016.4<?supplied-pmid 26768768?>26768768 </plain></SENT>
</text></ref><ref id="B126"><text><SENT sid="694" pm="."><plain>126.WangXXWangXLTongMMGanLChenHWuSS. SIRT6 protects cardiomyocytes against ischemia/reperfusion injury by augmenting FoxO3alpha-dependent antioxidant defense mechanisms. Basic Res Cardiol. </plain></SENT>
<SENT sid="695" pm="."><plain>(2016) 111:13. 10.1007/s00395-016-0531-z<?supplied-pmid 26786260?>26786260 </plain></SENT>
</text></ref><ref id="B127"><text><SENT sid="696" pm="."><plain>127.RyuDJoYSLoSasso GSteinSZhangHPerinoA. A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab. </plain></SENT>
<SENT sid="697" pm="."><plain>(2014) 20:856–69. 10.1016/j.cmet.2014.08.001<?supplied-pmid 25200183?>25200183 </plain></SENT>
</text></ref><ref id="B128"><text><SENT sid="698" pm="."><plain>128.MohrinMShinJLiuYBrownKLuoHXiY. Stem cell aging. </plain></SENT>
<SENT sid="699" pm="."><plain>A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. Science (2015) 347:1374–7. 10.1126/science.aaa2361<?supplied-pmid 25792330?>25792330 </plain></SENT>
</text></ref><ref id="B129"><text><SENT sid="700" pm="."><plain>129.XiongXSunXWangQQianXZhangYPanX. SIRT6 protects against palmitate-induced pancreatic beta-cell dysfunction and apoptosis. J Endocrinol. </plain></SENT>
<SENT sid="701" pm="."><plain>(2016) 231:159–65. 10.1530/JOE-16-0317<?supplied-pmid 27601447?>27601447 </plain></SENT>
</text></ref><ref id="B130"><text><SENT sid="702" pm="."><plain>130.QinKZhangNZhangZNipperMZhuZLeightonJ. SIRT6-mediated transcriptional suppression of Txnip is critical for pancreatic beta cell function and survival in mice. Diabetologia (2018) 61:906–18. 10.1007/s00125-017-4542-6<?supplied-pmid 29322219?>29322219 </plain></SENT>
</text></ref><ref id="B131"><text><SENT sid="703" pm="."><plain>131.MoynihanKAGrimmAAPluegerMMBernal-MizrachiEFordECras-MeneurC. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. </plain></SENT>
<SENT sid="704" pm="."><plain>(2005) 2:105–17. 10.1016/j.cmet.2005.07.001<?supplied-pmid 16098828?>16098828 </plain></SENT>
</text></ref><ref id="B132"><text><SENT sid="705" pm="."><plain>132.BordoneLMottaMCPicardFRobinsonAJhalaUSApfeldJ. SIRT1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol. </plain></SENT>
<SENT sid="706" pm="."><plain>(2006) 4:e31. 10.1371/journal.pbio.0040031<?supplied-pmid 16366736?>16366736 </plain></SENT>
</text></ref><ref id="B133"><text><SENT sid="707" pm="."><plain>133.KitamuraYIKitamuraTKruseJPRaumJCSteinRGuW. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. </plain></SENT>
<SENT sid="708" pm="."><plain>(2005) 2:153–63. 10.1016/j.cmet.2005.08.004<?supplied-pmid 16154098?>16154098 </plain></SENT>
</text></ref><ref id="B134"><text><SENT sid="709" pm="."><plain>134.AndersonKAHuynhFKFisher-WellmanKStuartJDPetersonBSDourosJD. SIRT4 is a lysine deacylase that controls leucine metabolism and insulin secretion. Cell Metab. </plain></SENT>
<SENT sid="710" pm="."><plain>(2017) 25:838-855.e815. 10.1016/j.cmet.2017.03.003<?supplied-pmid 28380376?>28380376 </plain></SENT>
</text></ref><ref id="B135"><text><SENT sid="711" pm="."><plain>135.LombardDBAltFWChengHLBunkenborgJStreeperRSMostoslavskyR. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. </plain></SENT>
<SENT sid="712" pm="."><plain>(2007) 27:8807–14. 10.1128/MCB.01636-07<?supplied-pmid 17923681?>17923681 </plain></SENT>
</text></ref><ref id="B136"><text><SENT sid="713" pm="."><plain>136.CatonPWRichardsonSJKieswichJBuglianiMHollandMLMarchettiP. Sirtuin 3 regulates mouse pancreatic beta cell function and is suppressed in pancreatic islets isolated from human type 2 diabetic patients. Diabetologia (2013) 56:1068–77. 10.1007/s00125-013-2851-y<?supplied-pmid 23397292?>23397292 </plain></SENT>
</text></ref><ref id="B137"><text><SENT sid="714" pm="."><plain>137.ZhouYChungACKFanRLeeHMXuGTomlinsonB. SIRT3 deficiency increased the vulnerability of pancreatic beta cells to oxidative stress-induced dysfunction. Antiox Redox Signal. </plain></SENT>
<SENT sid="715" pm="."><plain>(2017) 27:962–76. 10.1089/ars.2016.6859<?supplied-pmid 28375738?>28375738 </plain></SENT>
</text></ref><ref id="B138"><text><SENT sid="716" pm="."><plain>138.KimMLeeJSOhJENanJLeeHJungHS. SIRT3 Overexpression attenuates palmitate-induced pancreatic beta-cell dysfunction. PLoS ONE (2015) 10:e0124744. 10.1371/journal.pone.0124744<?supplied-pmid 25915406?>25915406 </plain></SENT>
</text></ref><ref id="B139"><text><SENT sid="717" pm="."><plain>139.ZhangHHMaXJWuLNZhaoYYZhangPYZhangYH. Sirtuin-3 (SIRT3) protects pancreatic beta-cells from endoplasmic reticulum (ER) stress-induced apoptosis and dysfunction. Mol Cell Biochem. </plain></SENT>
<SENT sid="718" pm="."><plain>(2016) 420:95–106. 10.1007/s11010-016-2771-5<?supplied-pmid 27449933?>27449933 </plain></SENT>
</text></ref><ref id="B140"><text><SENT sid="719" pm="."><plain>140.SongMYWangJKaSOBaeEJParkBH. Insulin secretion impairment in SIRT6 knockout pancreatic beta cells is mediated by suppression of the FoxO1-Pdx1-Glut2 pathway. Sci Rep. (2016) 6:30321. 10.1038/srep30321<?supplied-pmid 27457971?>27457971 </plain></SENT>
</text></ref><ref id="B141"><text><SENT sid="720" pm="."><plain>141.XiongXWangGTaoRWuPKonoTLiK. Sirtuin 6 regulates glucose-stimulated insulin secretion in mouse pancreatic beta cells. Diabetologia (2016) 59:151–60. 10.1007/s00125-015-3778-2<?supplied-pmid 26471901?>26471901 </plain></SENT>
</text></ref><ref id="B142"><text><SENT sid="721" pm="."><plain>142.TaniguchiCMEmanuelliBKahnCR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. </plain></SENT>
<SENT sid="722" pm="."><plain>(2006) 7:85–96. 10.1038/nrm1837<?supplied-pmid 16493415?>16493415 </plain></SENT>
</text></ref><ref id="B143"><text><SENT sid="723" pm="."><plain>143.ZhangJ. The direct involvement of SIRT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem. </plain></SENT>
<SENT sid="724" pm="."><plain>(2007) 282:34356–364. 10.1074/jbc.M706644200<?supplied-pmid 17901049?>17901049 </plain></SENT>
</text></ref><ref id="B144"><text><SENT sid="725" pm="."><plain>144.SundaresanNRPillaiVBWolfgeherDSamantSVasudevanPParekhV. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. </plain></SENT>
<SENT sid="726" pm="."><plain>(2011) 4:ra46. 10.1126/scisignal.2001465<?supplied-pmid 21775285?>21775285 </plain></SENT>
</text></ref><ref id="B145"><text><SENT sid="727" pm="."><plain>145.DanLKlimenkovaOKlimiankouMKlusmanJHvanden Heuvel-Eibrink MMReinhardtD. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica (2012) 97:551–9. 10.3324/haematol.2011.055236<?supplied-pmid 22207684?>22207684 </plain></SENT>
</text></ref><ref id="B146"><text><SENT sid="728" pm="."><plain>146.ChenJChanAWToKFChenWZhangZRenJ. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology (2013) 57:2287–98. 10.1002/hep.26278<?supplied-pmid 23348706?>23348706 </plain></SENT>
</text></ref><ref id="B147"><text><SENT sid="729" pm="."><plain>147.RamakrishnanGDavaakhuuGKaplunLChungWCRanaAAtfiA. SIRT2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin. J Biol Chem. </plain></SENT>
<SENT sid="730" pm="."><plain>(2014) 289:6054–66. 10.1074/jbc.M113.537266<?supplied-pmid 24446434?>24446434 </plain></SENT>
</text></ref><ref id="B148"><text><SENT sid="731" pm="."><plain>148.AroraADeyCS. SIRT2 negatively regulates insulin resistance in C2C12 skeletal muscle cells. Biochim Biophys Acta (2014) 1842:1372–8. 10.1016/j.bbadis.2014.04.027<?supplied-pmid 24793418?>24793418 </plain></SENT>
</text></ref><ref id="B149"><text><SENT sid="732" pm="."><plain>149.AroraADeyCS. SIRT2 regulates insulin sensitivity in insulin resistant neuronal cells. Biochem Biophys Res Commun. </plain></SENT>
<SENT sid="733" pm="."><plain>(2016) 474:747–52. 10.1016/j.bbrc.2016.05.029<?supplied-pmid 27163642?>27163642 </plain></SENT>
</text></ref><ref id="B150"><text><SENT sid="734" pm="."><plain>150.JingEGestaSKahnCR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. </plain></SENT>
<SENT sid="735" pm="."><plain>(2007) 6:105–14. 10.1016/j.cmet.2007.07.003<?supplied-pmid 17681146?>17681146 </plain></SENT>
</text></ref><ref id="B151"><text><SENT sid="736" pm="."><plain>151.BelmanJPBianRRHabtemichaelENLiDTJurczakMJAlcazar-RomanA. Acetylation of TUG protein promotes the accumulation of GLUT4 glucose transporters in an insulin-responsive intracellular compartment. J Biol Chem. </plain></SENT>
<SENT sid="737" pm="."><plain>(2015) 290:4447–63. 10.1074/jbc.M114.603977<?supplied-pmid 25561724?>25561724 </plain></SENT>
</text></ref><ref id="B152"><text><SENT sid="738" pm="."><plain>152.XiaoCKimHSLahusenTWangRHXuXGavrilovaO. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem. </plain></SENT>
<SENT sid="739" pm="."><plain>(2010) 285:36776–84. 10.1074/jbc.M110.168039<?supplied-pmid 20847051?>20847051 </plain></SENT>
</text></ref><ref id="B153"><text><SENT sid="740" pm="."><plain>153.AndersonJGRamadoriGIorisRMGalieMBerglundEDCoateKC. Enhanced insulin sensitivity in skeletal muscle and liver by physiological overexpression of SIRT6. Mol Metab. </plain></SENT>
<SENT sid="741" pm="."><plain>(2015) 4:846–56. 10.1016/j.molmet.2015.09.003<?supplied-pmid 26629408?>26629408 </plain></SENT>
</text></ref><ref id="B154"><text><SENT sid="742" pm="."><plain>154.YuJQinBWuFQinSNowsheenSShanS. Regulation of serine-threonine kinase Akt Activation by NAD+-dependent deacetylase SIRT7. Cell Rep. </plain></SENT>
<SENT sid="743" pm="."><plain>(2017) 18:1229–40. 10.1016/j.celrep.2017.01.009<?supplied-pmid 28147277?>28147277 </plain></SENT>
</text></ref><ref id="B155"><text><SENT sid="744" pm="."><plain>155.SaltielARKahnCR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature (2001) 414:799–806. 10.1038/414799a<?supplied-pmid 11742412?>11742412 </plain></SENT>
</text></ref><ref id="B156"><text><SENT sid="745" pm="."><plain>156.FarmerSR. Transcriptional control of adipocyte formation. Cell Metab. </plain></SENT>
<SENT sid="746" pm="."><plain>(2006) 4:263–273. 10.1016/j.cmet.2006.07.001<?supplied-pmid 17011499?>17011499 </plain></SENT>
</text></ref><ref id="B157"><text><SENT sid="747" pm="."><plain>157.PuigserverPRheeJDonovanJWalkeyCJYoonJCOrienteF. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature (2003) 423:550–5. 10.1038/nature01667<?supplied-pmid 12754525?>12754525 </plain></SENT>
</text></ref><ref id="B158"><text><SENT sid="748" pm="."><plain>158.BoucheCSerdySKahnCRGoldfineAB. The cellular fate of glucose and its relevance in type 2 diabetes. Endocrine Rev. </plain></SENT>
<SENT sid="749" pm="."><plain>(2004) 25:807–30. 10.1210/er.2003-0026<?supplied-pmid 15466941?>15466941 </plain></SENT>
</text></ref><ref id="B159"><text><SENT sid="750" pm="."><plain>159.WeyerCBogardusCMottDMPratleyRE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Investigat. </plain></SENT>
<SENT sid="751" pm="."><plain>(1999) 104:787–94. 10.1172/JCI7231<?supplied-pmid 10491414?>10491414 </plain></SENT>
</text></ref><ref id="B160"><text><SENT sid="752" pm="."><plain>160.SmithAGMuscatGE. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease. Int J Biochem Cell Biol. </plain></SENT>
<SENT sid="753" pm="."><plain>(2005) 37:2047–63. 10.1016/j.biocel.2005.03.002<?supplied-pmid 15922648?>15922648 </plain></SENT>
</text></ref><ref id="B161"><text><SENT sid="754" pm="."><plain>161.JingEO'NeillBTRardinMJKleinriddersAIlkeyevaORUssarS. SIRT3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes (2013) 62:3404–17. 10.2337/db12-1650<?supplied-pmid 23835326?>23835326 </plain></SENT>
</text></ref><ref id="B162"><text><SENT sid="755" pm="."><plain>162.PalaciosOMCarmonaJJMichanSChenKYManabeYWardJL. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging (2009) 1:771–783. 10.18632/aging.100075<?supplied-pmid 20157566?>20157566 </plain></SENT>
</text></ref><ref id="B163"><text><SENT sid="756" pm="."><plain>163.MilneJCLambertPDSchenkSCarneyDPSmithJJGagneDJ. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature (2007) 450:712–6. 10.1038/nature06261<?supplied-pmid 18046409?>18046409 </plain></SENT>
</text></ref><ref id="B164"><text><SENT sid="757" pm="."><plain>164.FrescasDValentiLAcciliD. Nuclear trapping of the forkhead transcription factor FoxO1 via SIRT-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem. </plain></SENT>
<SENT sid="758" pm="."><plain>(2005) 280:20589–95. 10.1074/jbc.M412357200<?supplied-pmid 15788402?>15788402 </plain></SENT>
</text></ref><ref id="B165"><text><SENT sid="759" pm="."><plain>165.RodgersJTLerinCHaasWGygiSPSpiegelmanBMPuigserverP. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature (2005) 434:113–8. 10.1038/nature03354<?supplied-pmid 15744310?>15744310 </plain></SENT>
</text></ref><ref id="B166"><text><SENT sid="760" pm="."><plain>166.LiuYDentinRChenDHedrickSRavnskjaerKSchenkS. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature (2008) 456:269–73. 10.1038/nature07349<?supplied-pmid 18849969?>18849969 </plain></SENT>
</text></ref><ref id="B167"><text><SENT sid="761" pm="."><plain>167.HallowsWCYuWDenuJM. Regulation of glycolytic enzyme phosphoglycerate mutase-1 by SIRT1 protein-mediated deacetylation. J Biol Chem. </plain></SENT>
<SENT sid="762" pm="."><plain>(2012) 287:3850–8. 10.1074/jbc.M111.317404<?supplied-pmid 22157007?>22157007 </plain></SENT>
</text></ref><ref id="B168"><text><SENT sid="763" pm="."><plain>168.LiYWongKGilesAJiangJLeeJWAdamsAC. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology (2014) 146:539–549.e537. 10.1053/j.gastro.2013.10.059<?supplied-pmid 24184811?>24184811 </plain></SENT>
</text></ref><ref id="B169"><text><SENT sid="764" pm="."><plain>169.LiYXuSGilesANakamuraKLeeJWHouX. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. (2011) 25:1664–79. 10.1096/fj.10-173492<?supplied-pmid 21321189?>21321189 </plain></SENT>
</text></ref><ref id="B170"><text><SENT sid="765" pm="."><plain>170.AjmoJMLiangXRogersCQPennockBYouM. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol. (2008) 295:G833–842. 10.1152/ajpgi.90358.2008<?supplied-pmid 18755807?>18755807 </plain></SENT>
</text></ref><ref id="B171"><text><SENT sid="766" pm="."><plain>171.YamazakiYUsuiIKanataniYMatsuyaYTsuneyamaKFujisakaS. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol. </plain></SENT>
<SENT sid="767" pm="."><plain>(2009) 297:E1179–1186. 10.1152/ajpendo.90997.2008<?supplied-pmid 19724016?>19724016 </plain></SENT>
</text></ref><ref id="B172"><text><SENT sid="768" pm="."><plain>172.WalkerAKYangFJiangKJiJYWattsJLPurushothamA. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. </plain></SENT>
<SENT sid="769" pm="."><plain>(2010) 24:1403–17. 10.1101/gad.1901210<?supplied-pmid 20595232?>20595232 </plain></SENT>
</text></ref><ref id="B173"><text><SENT sid="770" pm="."><plain>173.HouXXuSMaitland-ToolanKASatoKJiangBIdoY. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem. </plain></SENT>
<SENT sid="771" pm="."><plain>(2008) 283:20015–26. 10.1074/jbc.M802187200<?supplied-pmid 18482975?>18482975 </plain></SENT>
</text></ref><ref id="B174"><text><SENT sid="772" pm="."><plain>174.GestaSTsengYHKahnCR. Developmental origin of fat: tracking obesity to its source. Cell (2007) 131:242–56. 10.1016/j.cell.2007.10.004<?supplied-pmid 17956727?>17956727 </plain></SENT>
</text></ref><ref id="B175"><text><SENT sid="773" pm="."><plain>175.PicardFKurtevMChungNTopark-NgarmASenawongTMachadoDe Oliveira R. SIRT1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature (2004) 429:771–6. 10.1038/nature02583<?supplied-pmid 15175761?>15175761 </plain></SENT>
</text></ref><ref id="B176"><text><SENT sid="774" pm="."><plain>176.GuanHPLiYJensenMVNewgardCBSteppanCMLazarMA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med. </plain></SENT>
<SENT sid="775" pm="."><plain>(2002) 8:1122–8. 10.1038/nm780<?supplied-pmid 12357248?>12357248 </plain></SENT>
</text></ref><ref id="B177"><text><SENT sid="776" pm="."><plain>177.KelleyDEGoodpasterBHStorlienL. Muscle triglyceride and insulin resistance. Annu Rev Nutr. </plain></SENT>
<SENT sid="777" pm="."><plain>(2002) 22:325–46. 10.1146/annurev.nutr.22.010402.102912<?supplied-pmid 12055349?>12055349 </plain></SENT>
</text></ref><ref id="B178"><text><SENT sid="778" pm="."><plain>178.Gerhart-HinesZRodgersJTBareOLerinCKimSHMostoslavskyR. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. (2007) 26:1913–23. 10.1038/sj.emboj.7601633<?supplied-pmid 17347648?>17347648 </plain></SENT>
</text></ref><ref id="B179"><text><SENT sid="780" pm="."><plain>179.CantoCGerhart-HinesZFeigeJNLagougeMNoriegaLMilneJC. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 458:1056–60. 10.1038/nature07813<?supplied-pmid 19262508?>19262508 </plain></SENT>
</text></ref><ref id="B180"><text><SENT sid="781" pm="."><plain>180.FrojdoSDurandCMolinLCareyALEl-OstaAKingwellBA. Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol Cell Endocrinol. </plain></SENT>
<SENT sid="782" pm="."><plain>(2011) 335:166–76. 10.1016/j.mce.2011.01.008<?supplied-pmid 21241768?>21241768 </plain></SENT>
</text></ref><ref id="B181"><text><SENT sid="783" pm="."><plain>181.WhiteATMcCurdyCEPhilpAHamiltonDLJohnsonCDSchenkS. Skeletal muscle-specific overexpression of SIRT1 does not enhance whole-body energy expenditure or insulin sensitivity in young mice. Diabetologia (2013) 56:1629–37. 10.1007/s00125-013-2912-2<?supplied-pmid 23604553?>23604553 </plain></SENT>
</text></ref><ref id="B182"><text><SENT sid="784" pm="."><plain>182.WhiteATPhilpAFridolfssonHNSchillingJMMurphyANHamiltonDL High-fat diet-induced impairment of skeletal muscle insulin sensitivity is not prevented by SIRT1 overexpression. Am J Physiol. </plain></SENT>
<SENT sid="785" pm="."><plain>(2014) 307:E764–772. 10.1152/ajpendo.00001.2014 </plain></SENT>
</text></ref><ref id="B183"><text><SENT sid="786" pm="."><plain>183.CôtéCDRasmussenBADucaFAZadeh-TahmasebiMBaurJADaljeetM. Resveratrol activates duodenal SIRT1 to reverse insulin resistance in rats through a neuronal network. Nat Med. </plain></SENT>
<SENT sid="787" pm="."><plain>(2015) 21:498. 10.1038/nm.3821<?supplied-pmid 25849131?>25849131 </plain></SENT>
</text></ref><ref id="B184"><text><SENT sid="788" pm="."><plain>184.JamesRyall GDell'OrsoSDerfoulAJuanAZareHFengX The NAD+-dependent SIRT1 deacetylase translates a metabolic switch into regulatory epigenetics in skeletal muscle stem cells. Cell Stem Cell (2015) 16:171–83. 10.1016/j.stem.2014.12.00425600643 </plain></SENT>
</text></ref><ref id="B185"><text><SENT sid="789" pm="."><plain>185.GurdBJPerryCGRHeigenhauserGJFSprietLLBonenA. High-intensity interval training increases SIRT1 activity in human skeletal muscle. Appl Physiol Nutr Metab. (2010) 35:350–7. 10.1139/H10-030<?supplied-pmid 20555380?>20555380 </plain></SENT>
</text></ref><ref id="B186"><text><SENT sid="790" pm="."><plain>186.CrujeirasABParraDGoyenecheaEMartinezJA. Sirtuin gene expression in human mononuclear cells is modulated by caloric restriction. Eur J Clin Investig. </plain></SENT>
<SENT sid="791" pm="."><plain>(2008) 38:672–8. 10.1111/j.1365-2362.2008.01998.x<?supplied-pmid 18837744?>18837744 </plain></SENT>
</text></ref><ref id="B187"><text><SENT sid="792" pm="."><plain>187.KrishnanJDanzerCSimkaTUkropecJWalterKMKumpfS. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the SIRT2-NAD+ system. Genes Dev. </plain></SENT>
<SENT sid="793" pm="."><plain>(2012) 26:259–70. 10.1101/gad.180406.111<?supplied-pmid 22302938?>22302938 </plain></SENT>
</text></ref><ref id="B188"><text><SENT sid="794" pm="."><plain>188.ArabSadeghabadi ZNourbakhshMPasalarPEmamgholipourSGolestaniALarijaniB Reduced gene expression of sirtuins and active AMPK levels in children and adolescents with obesity and insulin resistance. Obes Res Clin Pract. </plain></SENT>
<SENT sid="795" pm="."><plain>(2018) 12:167–73. 10.1016/j.orcp.2017.10.00429150224 </plain></SENT>
</text></ref><ref id="B189"><text><SENT sid="796" pm="."><plain>189.NakaeJKitamuraTKitamuraYBiggsWH 3rdArdenKCAcciliD. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell (2003) 4:119–29. 10.1016/S1534-5807(02)00401-X<?supplied-pmid 12530968?>12530968 </plain></SENT>
</text></ref><ref id="B190"><text><SENT sid="797" pm="."><plain>190.DowellPOttoTCAdiSLaneMD. Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. J Biol Chem. </plain></SENT>
<SENT sid="798" pm="."><plain>(2003) 278:45485–91. 10.1074/jbc.M309069200<?supplied-pmid 12966085?>12966085 </plain></SENT>
</text></ref><ref id="B191"><text><SENT sid="799" pm="."><plain>191.ArmoniMHarelCKarniSChenHBar-YosephFVerMR. FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. </plain></SENT>
<SENT sid="800" pm="."><plain>A novel paradigm to increase insulin sensitivity. J Biol Chem. </plain></SENT>
<SENT sid="801" pm="."><plain>(2006) 281:19881–91. 10.1074/jbc.M600320200<?supplied-pmid 16670091?>16670091 </plain></SENT>
</text></ref><ref id="B192"><text><SENT sid="802" pm="."><plain>192.WangFTongQ. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARgamma. Mol Biol Cell (2009) 20:801–8. 10.1091/mbc.e08-06-0647<?supplied-pmid 19037106?>19037106 </plain></SENT>
</text></ref><ref id="B193"><text><SENT sid="803" pm="."><plain>193.StrableMSNtambiJM. Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol. </plain></SENT>
<SENT sid="804" pm="."><plain>(2010) 45:199–214. 10.3109/10409231003667500<?supplied-pmid 20218765?>20218765 </plain></SENT>
</text></ref><ref id="B194"><text><SENT sid="805" pm="."><plain>194.WellenKEHatzivassiliouGSachdevaUMBuiTVCrossJRThompsonCB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science (2009) 324:1076–80. 10.1126/science.1164097<?supplied-pmid 19461003?>19461003 </plain></SENT>
</text></ref><ref id="B195"><text><SENT sid="806" pm="."><plain>195.LinRTaoRGaoXLiTZhouXGuanKL. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell (2013) 51:506–18. 10.1016/j.molcel.2013.07.002<?supplied-pmid 23932781?>23932781 </plain></SENT>
</text></ref><ref id="B196"><text><SENT sid="807" pm="."><plain>196.VegaRBHussJMKellyDP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. </plain></SENT>
<SENT sid="808" pm="."><plain>(2000) 20:1868–76. 10.1128/MCB.20.5.1868-1876.2000<?supplied-pmid 10669761?>10669761 </plain></SENT>
</text></ref><ref id="B197"><text><SENT sid="809" pm="."><plain>197.ZhaoSXuWJiangWYuWLinYZhangT. Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 327:1000–4. 10.1126/science.1179689<?supplied-pmid 20167786?>20167786 </plain></SENT>
</text></ref><ref id="B198"><text><SENT sid="810" pm="."><plain>198.JiangWWangSXiaoMLinYZhouLLeiQ. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell (2011) 43:33–44. 10.1016/j.molcel.2011.04.028<?supplied-pmid 21726808?>21726808 </plain></SENT>
</text></ref><ref id="B199"><text><SENT sid="811" pm="."><plain>199.HerzigSLongFJhalaUSHedrickSQuinnRBauerA. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature (2001) 413:179–83. 10.1038/35093131<?supplied-pmid 11557984?>11557984 </plain></SENT>
</text></ref><ref id="B200"><text><SENT sid="812" pm="."><plain>200.NakaeJBiggsWH 3rdKitamuraTCaveneeWKWrightCVArdenKC. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet. </plain></SENT>
<SENT sid="813" pm="."><plain>(2002) 32:245–53. 10.1038/ng890<?supplied-pmid 12219087?>12219087 </plain></SENT>
</text></ref><ref id="B201"><text><SENT sid="814" pm="."><plain>201.YoonJCPuigserverPChenGDonovanJWuZRheeJ. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature (2001) 413:131–8. 10.1038/35093050<?supplied-pmid 11557972?>11557972 </plain></SENT>
</text></ref><ref id="B202"><text><SENT sid="815" pm="."><plain>202.OnyangoPCelicIMcCafferyJMBoekeJDFeinbergAP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA (2002) 99:13653–8. 10.1073/pnas.222538099<?supplied-pmid 12374852?>12374852 </plain></SENT>
</text></ref><ref id="B203"><text><SENT sid="816" pm="."><plain>203.SuAIWiltshireTBatalovSLappHChingKABlockD. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA (2004) 101:6062–7. 10.1073/pnas.0400782101<?supplied-pmid 15075390?>15075390 </plain></SENT>
</text></ref><ref id="B204"><text><SENT sid="817" pm="."><plain>204.WuCOrozcoCBoyerJLegliseMGoodaleJBatalovS. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. </plain></SENT>
<SENT sid="818" pm="."><plain>(2009) 10:R130. 10.1186/gb-2009-10-11-r130<?supplied-pmid 19919682?>19919682 </plain></SENT>
</text></ref><ref id="B205"><text><SENT sid="819" pm="."><plain>205.HanEHilsenbeckSGRichardsonANelsonJF. cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction. Mech Ageing Dev. </plain></SENT>
<SENT sid="820" pm="."><plain>(2000) 115:157–74. 10.1016/S0047-6374(00)00119-6<?supplied-pmid 10906510?>10906510 </plain></SENT>
</text></ref><ref id="B206"><text><SENT sid="821" pm="."><plain>206.ShiTWangFStierenETongQ. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. </plain></SENT>
<SENT sid="822" pm="."><plain>(2005) 280:13560–7. 10.1074/jbc.M414670200<?supplied-pmid 15653680?>15653680 </plain></SENT>
</text></ref><ref id="B207"><text><SENT sid="823" pm="."><plain>207.SchwerBEckersdorffMLiYSilvaJCFerminDKurtevMV. Calorie restriction alters mitochondrial protein acetylation. Aging Cell (2009) 8:604–6. 10.1111/j.1474-9726.2009.00503.x<?supplied-pmid 19594485?>19594485 </plain></SENT>
</text></ref><ref id="B208"><text><SENT sid="824" pm="."><plain>208.HallowsWCYuWSmithBCDevriesMKEllingerJJSomeyaS. SIRT3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell (2011) 41:139–49. 10.1016/j.molcel.2011.01.002<?supplied-pmid 21255725?>21255725 </plain></SENT>
</text></ref><ref id="B209"><text><SENT sid="825" pm="."><plain>209.HirscheyMDShimazuTJingEGrueterCACollinsAMAouizeratB. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 44:177–90. 10.1016/j.molcel.2011.07.019<?supplied-pmid 21856199?>21856199 </plain></SENT>
</text></ref><ref id="B210"><text><SENT sid="826" pm="."><plain>210.HirscheyMDShimazuTGoetzmanEJingESchwerBLombardDB. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature (2010) 464:121–5. 10.1038/nature08778<?supplied-pmid 20203611?>20203611 </plain></SENT>
</text></ref><ref id="B211"><text><SENT sid="827" pm="."><plain>211.Garcia-FuentesESantiago-FernandezCGutierrez-RepisoCMayasMDOliva-OliveraWCoin-AraguezL. Hypoxia is associated with a lower expression of genes involved in lipogenesis in visceral adipose tissue. J Transl Med. </plain></SENT>
<SENT sid="828" pm="."><plain>(2015) 13:373. 10.1186/s12967-015-0732-5<?supplied-pmid 26619907?>26619907 </plain></SENT>
</text></ref><ref id="B212"><text><SENT sid="829" pm="."><plain>212.Zamora-MendozaRRosas-VargasHRamos-CervantesMTGarcia-ZunigaPPerez-LorenzanaHMendoza-LorenzoP. Dysregulation of mitochondrial function and biogenesis modulators in adipose tissue of obese children. Int J Obes. </plain></SENT>
<SENT sid="830" pm="."><plain>(2018) 42:618–24. 10.1038/ijo.2017.274<?supplied-pmid 29158541?>29158541 </plain></SENT>
</text></ref><ref id="B213"><text><SENT sid="831" pm="."><plain>213.KurtzDMRinaldoPRheadWJTianLMillingtonDSVockleyJ. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci USA (1998) 95:15592–7. 10.1073/pnas.95.26.15592<?supplied-pmid 9861014?>9861014 </plain></SENT>
</text></ref><ref id="B214"><text><SENT sid="832" pm="."><plain>214.ZhangDLiuZXChoiCSTianLKibbeyRDongJ Shulman GI, Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci USA (2007) 104:17075–80. 10.1073/pnas.070706010417940018 </plain></SENT>
</text></ref><ref id="B215"><text><SENT sid="833" pm="."><plain>215.Fernandez-MarcosPJJeningaEHCantoCHarachTdeBoer VCAndreuxP. Muscle or liver-specific SIRT3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Sci Rep. </plain></SENT>
<SENT sid="834" pm="."><plain>(2012) 2:425. 10.1038/srep00425<?supplied-pmid 22645641?>22645641 </plain></SENT>
</text></ref><ref id="B216"><text><SENT sid="835" pm="."><plain>216.YechoorVKPattiMEUekiKLaustsenPGSacconeRRauniyarR. Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. Proc Natl Acad Sci USA (2004) 101:16525–30. 10.1073/pnas.0407574101<?supplied-pmid 15546994?>15546994 </plain></SENT>
</text></ref><ref id="B217"><text><SENT sid="836" pm="."><plain>217.LantierLWilliamsASWilliamsIMYangKKBracyDPGoelzerM. SIRT3 is crucial for maintaining skeletal muscle insulin action and protects against severe insulin resistance in high-fat-fed mice. Diabetes (2015) 64:3081–92. 10.2337/db14-1810<?supplied-pmid 25948682?>25948682 </plain></SENT>
</text></ref><ref id="B218"><text><SENT sid="837" pm="."><plain>218.ChenYRFangSRFuYCZhouXHXuMYXuWC. Calorie restriction on insulin resistance and expression of SIRT1 and SIRT4 in rats. Biochem Cell Biol. </plain></SENT>
<SENT sid="838" pm="."><plain>(2010) 88:715–22. 10.1139/O10-010<?supplied-pmid 20651844?>20651844 </plain></SENT>
</text></ref><ref id="B219"><text><SENT sid="839" pm="."><plain>219.dePinho LAndradeJMParaisoAFilhoABFeltenbergerJDGuimaraesAL Diet composition modulates expression of sirtuins and renin-angiotensin system components in adipose tissue. Obesity (2013) 21:1830–5. 10.1002/oby.2030523408648 </plain></SENT>
</text></ref><ref id="B220"><text><SENT sid="840" pm="."><plain>220.LaurentGGermanNJSahaAKdeBoer VCDaviesMKovesTR. SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell (2013) 50:686–98. 10.1016/j.molcel.2013.05.012<?supplied-pmid 23746352?>23746352 </plain></SENT>
</text></ref><ref id="B221"><text><SENT sid="841" pm="."><plain>221.LaurentGdeBoer VCFinleyLWSweeneyMLuHSchugTT. SIRT4 represses peroxisome proliferator-activated receptor alpha activity to suppress hepatic fat oxidation. Mol Cell Biol. </plain></SENT>
<SENT sid="842" pm="."><plain>(2013) 33:4552–61. 10.1128/MCB.00087-13<?supplied-pmid 24043310?>24043310 </plain></SENT>
</text></ref><ref id="B222"><text><SENT sid="843" pm="."><plain>222.WuTLiuYHFuYCLiuXMZhouXH. Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients. Ann Clin Labor Sci. </plain></SENT>
<SENT sid="844" pm="."><plain>(2014) 44:410–8. <?supplied-pmid 25361925?>25361925 </plain></SENT>
</text></ref><ref id="B223"><text><SENT sid="845" pm="."><plain>223.RardinMJHeWNishidaYNewmanJCCarricoCDanielsonSR. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab. </plain></SENT>
<SENT sid="846" pm="."><plain>(2013) 18:920–33. 10.1016/j.cmet.2013.11.013<?supplied-pmid 24315375?>24315375 </plain></SENT>
</text></ref><ref id="B224"><text><SENT sid="847" pm="."><plain>224.ParkJChenYTishkoffDXPengCTanMDaiL. SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell (2013) 50:919–30. 10.1016/j.molcel.2013.06.001<?supplied-pmid 23806337?>23806337 </plain></SENT>
</text></ref><ref id="B225"><text><SENT sid="848" pm="."><plain>225.YuJSadhukhanSNoriegaLGMoullanNHeBWeissRS. Metabolic characterization of a SIRT5 deficient mouse model. Sci Rep. </plain></SENT>
<SENT sid="849" pm="."><plain>(2013) 3:2806. 10.1038/srep02806<?supplied-pmid 24076663?>24076663 </plain></SENT>
</text></ref><ref id="B226"><text><SENT sid="850" pm="."><plain>226.JukarainenSHeinonenSRamoJTRinnankoski-TuikkaRRappouETummersM. Obesity is associated with low NAD(+)/SIRT pathway expression in adipose tissue of BMI-discordant monozygotic twins. J Clin Endocrinol Metab. </plain></SENT>
<SENT sid="851" pm="."><plain>(2016) 101:275–83. 10.1210/jc.2015-3095<?supplied-pmid 26574954?>26574954 </plain></SENT>
</text></ref><ref id="B227"><text><SENT sid="852" pm="."><plain>227.NishidaYRardinMJCarricoCHeWSahuAKGutP. SIRT5 Regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target. Mol Cell (2015) 59:321–32. 10.1016/j.molcel.2015.05.022<?supplied-pmid 26073543?>26073543 </plain></SENT>
</text></ref><ref id="B228"><text><SENT sid="853" pm="."><plain>228.DominyJE JrLeeYJedrychowskiMPChimHJurczakMJCamporezJP. The deacetylase SIRT6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol Cell (2012) 48:900–13. 10.1016/j.molcel.2012.09.030<?supplied-pmid 23142079?>23142079 </plain></SENT>
</text></ref><ref id="B229"><text><SENT sid="854" pm="."><plain>229.MoschenARWieserVGernerRRBichlerAEnrichBMoserP. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol. </plain></SENT>
<SENT sid="855" pm="."><plain>(2013) 59:1315–22. 10.1016/j.jhep.2013.07.027<?supplied-pmid 23928404?>23928404 </plain></SENT>
</text></ref><ref id="B230"><text><SENT sid="856" pm="."><plain>230.ChenQHaoWXiaoCWangRXuXLuH. SIRT6 is essential for adipocyte differentiation by regulating mitotic clonal expansion. Cell Rep. </plain></SENT>
<SENT sid="857" pm="."><plain>(2017) 18:3155–66. 10.1016/j.celrep.2017.03.006<?supplied-pmid 28355567?>28355567 </plain></SENT>
</text></ref><ref id="B231"><text><SENT sid="858" pm="."><plain>231.KanfiYPeshtiVGilRNaimanSNahumLLevinE. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell (2010) 9:162–73. 10.1111/j.1474-9726.2009.00544.x<?supplied-pmid 20047575?>20047575 </plain></SENT>
</text></ref><ref id="B232"><text><SENT sid="859" pm="."><plain>232.YaoLCuiXChenQYangXFangFZhangJ. Cold-inducible SIRT6 regulates thermogenesis of brown and beige fat. Cell Rep. </plain></SENT>
<SENT sid="860" pm="."><plain>(2017) 20:641–54. 10.1016/j.celrep.2017.06.069<?supplied-pmid 28723567?>28723567 </plain></SENT>
</text></ref><ref id="B233"><text><SENT sid="861" pm="."><plain>233.ZhongLD'UrsoAToiberDSebastianCHenryREVadysirisackDD. The histone deacetylase SIRT6 regulates glucose homeostasis via Hif1alpha. Cell (2010) 140:280–93. 10.1016/j.cell.2009.12.041<?supplied-pmid 20141841?>20141841 </plain></SENT>
</text></ref><ref id="B234"><text><SENT sid="862" pm="."><plain>234.ZhangPTuBWangHCaoZTangMZhangC. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc Natl Acad Sci USA (2014) 111:10684–9. 10.1073/pnas.1411026111<?supplied-pmid 25009184?>25009184 </plain></SENT>
</text></ref><ref id="B235"><text><SENT sid="863" pm="."><plain>235.KimHSXiaoCWangRHLahusenTXuXVassilopoulosA. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab. </plain></SENT>
<SENT sid="864" pm="."><plain>(2010) 12:224–36. 10.1016/j.cmet.2010.06.009<?supplied-pmid 20816089?>20816089 </plain></SENT>
</text></ref><ref id="B236"><text><SENT sid="865" pm="."><plain>236.YangSJChoiJMChaeSWKimWJParkSERheeEJ. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases SIRT6 expression and ameliorates hepatic steatosis in rats. PLoS ONE (2011) 6:e17057. 10.1371/journal.pone.0017057<?supplied-pmid 21373642?>21373642 </plain></SENT>
</text></ref><ref id="B237"><text><SENT sid="866" pm="."><plain>237.CuiXYaoLYangXGaoYFangFZhangJ. SIRT6 regulates metabolic homeostasis in skeletal muscle through activation of AMPK. Am J Physiol Endocrinol Metab. </plain></SENT>
<SENT sid="867" pm="."><plain>(2017) 313:E493–E505. 10.1152/ajpendo.00122.2017<?supplied-pmid 28765271?>28765271 </plain></SENT>
</text></ref><ref id="B238"><text><SENT sid="868" pm="."><plain>238.KurylowiczAOwczarzMPolosakJJonasMILisikWJonasM SIRT1 and SIRT7 expression in adipose tissues of obese and normal-weight individuals is regulated by microRNAs but not by methylation status. Int J Obes. </plain></SENT>
<SENT sid="869" pm="."><plain>(2016) 40:1635–42. 10.1038/ijo.2016.131 </plain></SENT>
</text></ref><ref id="B239"><text><SENT sid="870" pm="."><plain>239.YoshizawaTKarimMFSatoYSenokuchiTMiyataKFukudaT. SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin-proteasome pathway. Cell Metab. </plain></SENT>
<SENT sid="871" pm="."><plain>(2014) 19:712–21. 10.1016/j.cmet.2014.03.006<?supplied-pmid 24703702?>24703702 </plain></SENT>
</text></ref><ref id="B240"><text><SENT sid="872" pm="."><plain>240.FangJIanniASmolkaCVakhrushevaONolteHKrugerM. SIRT7 promotes adipogenesis in the mouse by inhibiting autocatalytic activation of SIRT1. Proc Natl Acad Sci USA (2017) 114:E8352–E8361. 10.1073/pnas.1706945114<?supplied-pmid 28923965?>28923965 </plain></SENT>
</text></ref><ref id="B241"><text><SENT sid="873" pm="."><plain>241.CioffiMVallespinos-SerranoMSaraTrabulo MPabloFernandez-Marcos JAshleyFirment NBertaVazquez N. MiR-93 Controls Adiposity via Inhibition of SIRT7 and Tbx3. Cell Rep. </plain></SENT>
<SENT sid="874" pm="."><plain>(2015) 12:1594–605. 10.1016/j.celrep.2015.08.006<?supplied-pmid 26321631?>26321631 </plain></SENT>
</text></ref><ref id="B242"><text><SENT sid="875" pm="."><plain>242.ShinJHeMLiuYParedesSVillanovaLBrownK. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. </plain></SENT>
<SENT sid="876" pm="."><plain>(2013) 5:654–65. 10.1016/j.celrep.2013.10.007<?supplied-pmid 24210820?>24210820 </plain></SENT>
</text></ref><ref id="B243"><text><SENT sid="877" pm="."><plain>243.KangHSOkamotoKKimYSTakedaYBortnerCDDangH. Nuclear orphan receptor TAK1/TR4-deficient mice are protected against obesity-linked inflammation, hepatic steatosis, and insulin resistance. Diabetes (2011) 60:177–88. 10.2337/db10-0628<?supplied-pmid 20864514?>20864514 </plain></SENT>
</text></ref><ref id="B244"><text><SENT sid="878" pm="."><plain>244.HuHZhuWQinJChenMGongLLiL. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology (2017) 65:515–28. 10.1002/hep.28887<?supplied-pmid 27774669?>27774669 </plain></SENT>
</text></ref><ref id="B245"><text><SENT sid="879" pm="."><plain>245.JiangLXiongJZhanJYuanFTangMZhangC. Ubiquitin-specific peptidase 7 (USP7)-mediated deubiquitination of the histone deacetylase SIRT7 regulates gluconeogenesis. J Biol Chem. </plain></SENT>
<SENT sid="880" pm="."><plain>(2017) 292:13296–311. 10.1074/jbc.M117.780130<?supplied-pmid 28655758?>28655758 </plain></SENT>
</text></ref><ref id="B246"><text><SENT sid="881" pm="."><plain>246.HallJADominyJELeeYPuigserverP. The sirtuin family's role in aging and age-associated pathologies. J Clin Investig. </plain></SENT>
<SENT sid="882" pm="."><plain>(2013) 123:973–9. 10.1172/JCI64094<?supplied-pmid 23454760?>23454760 </plain></SENT>
</text></ref><ref id="B247"><text><SENT sid="883" pm="."><plain>247.PetersenKFBefroyDDufourSDziuraJAriyanCRothmanDL. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science (2003) 300:1140–2. 10.1126/science.1082889<?supplied-pmid 12750520?>12750520 </plain></SENT>
</text></ref><ref id="B248"><text><SENT sid="884" pm="."><plain>248.ParkMHKimDHLeeEKKimNDImDSLeeJ. Age-related inflammation and insulin resistance: a review of their intricate interdependency. Arch Pharm Res. </plain></SENT>
<SENT sid="885" pm="."><plain>(2014) 37:1507–14. 10.1007/s12272-014-0474-6<?supplied-pmid 25239110?>25239110 </plain></SENT>
</text></ref><ref id="B249"><text><SENT sid="886" pm="."><plain>249.FabbriEChiaCWSpencerRGFishbeinKWReiterDACameronD. Insulin resistance is associated with reduced mitochondrial oxidative capacity measured by 31P-magnetic resonance spectroscopy in participants without diabetes from the baltimore longitudinal study of aging. Diabetes (2017) 66:170–6. 10.2337/db16-0754<?supplied-pmid 27737951?>27737951 </plain></SENT>
</text></ref><ref id="B250"><text><SENT sid="887" pm="."><plain>250.WuHBallantyneCM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Investig. </plain></SENT>
<SENT sid="888" pm="."><plain>(2017) 127:43–54. 10.1172/JCI88880<?supplied-pmid 28045398?>28045398 </plain></SENT>
</text></ref><ref id="B251"><text><SENT sid="889" pm="."><plain>251.FinkelTDengCX Mostoslavsky R, Recent progress in the biology and physiology of sirtuins. Nature (2009) 460:587–91. 10.1038/nature0819719641587 </plain></SENT>
</text></ref><ref id="B252"><text><SENT sid="890" pm="."><plain>252.TangXChenXFWangNYWangXMLiangSTZhengW. SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy. Circulation (2017) 136:2051–67. 10.1161/CIRCULATIONAHA.117.028728<?supplied-pmid 28947430?>28947430 </plain></SENT>
</text></ref><ref id="B253"><text><SENT sid="891" pm="."><plain>253.KanfiYNaimanSAmirGPeshtiVZinmanGNahumL. The sirtuin SIRT6 regulates lifespan in male mice. Nature (2012) 483:218. 10.1038/nature10815<?supplied-pmid 22367546?>22367546 </plain></SENT>
</text></ref><ref id="B254"><text><SENT sid="892" pm="."><plain>254.SundaresanNRVasudevanPZhongLKimGSamantSParekhV. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. (2012) 18:1643. 10.1038/nm.2961<?supplied-pmid 23086477?>23086477 </plain></SENT>
</text></ref><ref id="B255"><text><SENT sid="893" pm="."><plain>255.SatohABraceCSRensingNCliftenPWozniakDFHerzogED. SIRT1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. </plain></SENT>
<SENT sid="894" pm="."><plain>(2013) 18:416–30. 10.1016/j.cmet.2013.07.013<?supplied-pmid 24011076?>24011076 </plain></SENT>
</text></ref><ref id="B256"><text><SENT sid="895" pm="."><plain>256.SarahMitchell JMartin-MontalvoAEviMercken MHectorPalacios HTheresaWard MAbulwerdiG The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. </plain></SENT>
<SENT sid="896" pm="."><plain>(2014) 6:836–43. 10.1016/j.celrep.2014.01.03124582957 </plain></SENT>
</text></ref><ref id="B257"><text><SENT sid="897" pm="."><plain>257.MadeoFPietrocolaFEisenbergTKroemerG. Caloric restriction mimetics: towards a molecular definition. Nat Rev Drug Discov. (2014) 13:727–40. 10.1038/nrd4391<?supplied-pmid 25212602?>25212602 </plain></SENT>
</text></ref><ref id="B258"><text><SENT sid="898" pm="."><plain>258.ChenHZWangFGaoPPeiJFLiuYXuTT. Age-associated sirtuin 1 reduction in vascular smooth muscle links vascular senescence and inflammation to abdominal aortic aneurysm. Circ Res. </plain></SENT>
<SENT sid="899" pm="."><plain>(2016) 119:1076–88. 10.1161/CIRCRESAHA.116.308895<?supplied-pmid 27650558?>27650558 </plain></SENT>
</text></ref><ref id="B259"><text><SENT sid="900" pm="."><plain>259.LiuYWangTTZhangRFuWYWangXWangF. Calorie restriction protects against experimental abdominal aortic aneurysms in mice. J Exp Med. </plain></SENT>
<SENT sid="901" pm="."><plain>(2016) 213:2473–88. 10.1084/jem.20151794<?supplied-pmid 27670594?>27670594 </plain></SENT>
</text></ref><ref id="B260"><text><SENT sid="902" pm="."><plain>260.WinnikSAuwerxJSinclairDAMatterCM. Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Eur Heart J. (2015) 36:3404–12. 10.1093/eurheartj/ehv290<?supplied-pmid 26112889?>26112889 </plain></SENT>
</text></ref><ref id="B261"><text><SENT sid="904" pm="."><plain>261.WeissEPRacetteSBVillarealDTFontanaLSteger-MayKSchechtmanKB. Washington University School of Medicine, Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr. </plain></SENT>
<SENT sid="905" pm="."><plain>(2006) 84:1033–42. 10.1093/ajcn/84.5.1033<?supplied-pmid 17093155?>17093155 </plain></SENT>
</text></ref><ref id="B262"><text><SENT sid="906" pm="."><plain>262.MeehanCACochranEMattinglyMGordenPBrownRJ. Mild caloric restriction decreases insulin requirements in patients with type 2 diabetes and severe insulin resistance. Medicine (2015) 94:e1160. 10.1097/MD.0000000000001160<?supplied-pmid 26222846?>26222846 </plain></SENT>
</text></ref><ref id="B263"><text><SENT sid="907" pm="."><plain>263.HoutkooperRHPirinenEAuwerxJ. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. </plain></SENT>
<SENT sid="908" pm="."><plain>(2012) 13:225–38. 10.1038/nrm3293<?supplied-pmid 22395773?>22395773 </plain></SENT>
</text></ref><ref id="B264"><text><SENT sid="909" pm="."><plain>264.Martin-MontalvoAMerckenEMMitchellSJPalaciosHHMotePLScheibye-KnudsenM. improves healthspan and lifespan in mice. Nat Commun. </plain></SENT>
<SENT sid="910" pm="."><plain>(2013) 4:2192. 10.1038/ncomms3192<?supplied-pmid 23900241?>23900241 </plain></SENT>
</text></ref><ref id="B265"><text><SENT sid="911" pm="."><plain>265.MirandaMXvanTits LJLohmannCArsiwalaTWinnikSTailleuxA The SIRT1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J. (2015) 36:51–9. 10.1093/eurheartj/ehu09524603306 </plain></SENT>
</text></ref><ref id="B266"><text><SENT sid="913" pm="."><plain>266.IgarashiMGuarenteL. mTORC1 and SIRT1 cooperate to foster expansion of gut adult stem cells during calorie restriction. Cell (2016) 166:436–50. 10.1016/j.cell.2016.05.044<?supplied-pmid 27345368?>27345368 </plain></SENT>
</text></ref><ref id="B267"><text><SENT sid="914" pm="."><plain>267.LaiYCTabimaDMDubeJJHughanKSVanderpoolRRGoncharovDA. SIRT3–AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation (2016) 133:717–31. 10.1161/CIRCULATIONAHA.115.018935<?supplied-pmid 26813102?>26813102 </plain></SENT>
</text></ref><ref id="B268"><text><SENT sid="915" pm="."><plain>268.DingYNTangXChenHZLiuDP. Epigenetic regulation of vascular aging and age-related vascular diseases, In: Wang Z, editor. Aging and Aging-Related Diseases: Mechanisms and Interventions. Singapore: Springer (2018). p. 55–75. 10.1007/978-981-13-1117-8_4<?supplied-pmid 30232752?> </plain></SENT>
</text></ref><ref id="B269"><text><SENT sid="916" pm="."><plain>269.BonkowskiMSSinclairDA. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. </plain></SENT>
<SENT sid="917" pm="."><plain>(2016) 17:679. 10.1038/nrm.2016.93<?supplied-pmid 27552971?>27552971 </plain></SENT>
</text></ref><ref id="B270"><text><SENT sid="918" pm="."><plain>270.MasriSRigorPCervantesMCegliaNSebastianCXiaoC. Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism. Cell (2014) 158:659–72. 10.1016/j.cell.2014.06.050<?supplied-pmid 25083875?>25083875 </plain></SENT>
</text></ref><ref id="B271"><text><SENT sid="919" pm="."><plain>271.VilleneuveLMReddyMALantingLLWangMMengLNatarajanR. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA (2008) 105:9047–52. 10.1073/pnas.0803623105<?supplied-pmid 18579779?>18579779 </plain></SENT>
</text></ref><ref id="B272"><text><SENT sid="920" pm="."><plain>272.RaychaudhuriNThamotharanSSrinivasanMMahmoodSPatelMSDevaskarSU. Postnatal exposure to a high-carbohydrate diet interferes epigenetically with thyroid hormone receptor induction of the adult male rat skeletal muscle glucose transporter isoform 4 expression. J Nutr Biochem. </plain></SENT>
<SENT sid="921" pm="."><plain>(2014) 25:1066–76. 10.1016/j.jnutbio.2014.05.011<?supplied-pmid 25086780?>25086780 </plain></SENT>
</text></ref><ref id="B273"><text><SENT sid="922" pm="."><plain>273.YangBYangJBaiJPuPLiuJWangF. SUV39H1 protects from myocardial ischemia-reperfusion injury in diabetic rats. Cell Physiol Biochem. (2014) 33:1176–85. 10.1159/000358686<?supplied-pmid 24752040?>24752040 </plain></SENT>
</text></ref><ref id="B274"><text><SENT sid="923" pm="."><plain>274.JiangZShiDTuYTianJZhangWXingB. Human proislet peptide promotes pancreatic progenitor cells to ameliorate diabetes through FOXO1/menin-mediated epigenetic regulation. Diabetes (2018) 67:1345–55. 10.2337/db17-0885<?supplied-pmid 29716892?>29716892 </plain></SENT>
</text></ref><ref id="B275"><text><SENT sid="924" pm="."><plain>275.TianYWongVWWongGLYangWSunHShenJ. Histone deacetylase HDAC8 promotes insulin resistance and beta-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res. </plain></SENT>
<SENT sid="925" pm="."><plain>(2015) 75:4803–16. 10.1158/0008-5472.CAN-14-3786<?supplied-pmid 26383163?>26383163 </plain></SENT>
</text></ref><ref id="B276"><text><SENT sid="926" pm="."><plain>276.ShiHMunkANielsenTSDaughtryMRLarssonLLiS. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity. Mol Metab. </plain></SENT>
<SENT sid="927" pm="."><plain>(2018) 11:160–77. 10.1016/j.molmet.2018.02.010<?supplied-pmid 29525407?>29525407 </plain></SENT>
</text></ref><ref id="B277"><text><SENT sid="928" pm="."><plain>277.VaqueroAScherMErdjument-BromageHTempstPSerranoLReinbergD. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature (2007) 450:440–4. 10.1038/nature06268<?supplied-pmid 18004385?>18004385 </plain></SENT>
</text></ref><ref id="B278"><text><SENT sid="929" pm="."><plain>278.Bosch-PresegueLRaurell-VilaHMarazuela-DuqueAKane-GoldsmithNValleAOliverJ. Stabilization of SUV39H1 by SIRT1 is part of oxidative stress response and ensures genome protection. Mol Cell (2011) 42:210–23. 10.1016/j.molcel.2011.02.034<?supplied-pmid 21504832?>21504832 </plain></SENT>
</text></ref><ref id="B279"><text><SENT sid="930" pm="."><plain>279.YangGZhangXWengXLiangPDaiXZengS. SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury. Basic Res Cardiol. </plain></SENT>
<SENT sid="931" pm="."><plain>(2017) 112:22. 10.1007/s00395-017-0608-3<?supplied-pmid 28271186?>28271186 </plain></SENT>
</text></ref><ref id="B280"><text><SENT sid="932" pm="."><plain>280.RenJHHuJLChengSTYuHBWongVKWLawBYK SIRT3 restricts HBV transcription and replication via epigenetic regulation of cccDNA involving SUV39H1 and SETD1A histone methyltransferases. Hepatology (2018) 68:1260–76. 10.1002/hep.2991229624717 </plain></SENT>
</text></ref><ref id="B281"><text><SENT sid="933" pm="."><plain>281.KumariPPopescuDYueSBoberEIanniABraunT. SIRT7 inhibits SIRT1-mediated activation of SUV39H1. Cell Cycle (2018) 17:1403–12. 10.1080/15384101.2018.1486166<?supplied-pmid 29963979?>29963979 </plain></SENT>
</text></ref><ref id="B282"><text><SENT sid="934" pm="."><plain>282.ShuYNDongLHLiHPeiQQMiaoSBZhangF. CKII-SIRT1-SM22alpha loop evokes a self-limited inflammatory response in vascular smooth muscle cells. Cardiovasc Res. </plain></SENT>
<SENT sid="935" pm="."><plain>(2017) 113:1198–207. 10.1093/cvr/cvx048<?supplied-pmid 28419207?>28419207 </plain></SENT>
</text></ref><ref id="B283"><text><SENT sid="936" pm="."><plain>283.LiMHongWHaoCLiLWuDShenA. SIRT1 antagonizes liver fibrosis by blocking hepatic stellate cell activation in mice. FASEB J. (2018) 32:500–11. 10.1096/fj.201700612R<?supplied-pmid 28970250?>28970250 </plain></SENT>
</text></ref><ref id="B284"><text><SENT sid="937" pm="."><plain>284.XuWJiangKShenMQianYPengY. SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A. Biol Chem. </plain></SENT>
<SENT sid="938" pm="."><plain>(2015) 396:929–36. 10.1515/hsz-2014-0284<?supplied-pmid 25719312?>25719312 </plain></SENT>
</text></ref><ref id="B285"><text><SENT sid="939" pm="."><plain>285.BakerDJChildsBGDurikMWijersMESiebenCJZhongJ. Naturally occurring p16 Ink4a-positive cells shorten healthy lifespan. Nature (2016) 530:184. 10.1038/nature16932<?supplied-pmid 26840489?>26840489 </plain></SENT>
</text></ref><ref id="B286"><text><SENT sid="940" pm="."><plain>286.ChildsBGBakerDJWijshakeTConoverCACampisiJvanDeursen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science (2016) 354:472–7. 10.1126/science.aaf6659<?supplied-pmid 27789842?>27789842 </plain></SENT>
</text></ref><ref id="B287"><text><SENT sid="941" pm="."><plain>287.ChildsBGLiHvan DeursenJM. Senescent cells: a therapeutic target for cardiovascular disease. J Clin Invest. </plain></SENT>
<SENT sid="942" pm="."><plain>(2018) 128:1217–28. 10.1172/JCI95146<?supplied-pmid 29608141?>29608141 </plain></SENT>
</text></ref><ref id="B288"><text><SENT sid="943" pm="."><plain>288.JeonOHKimCLabergeRMDemariaMRathodSVasserotAP. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. </plain></SENT>
<SENT sid="944" pm="."><plain>(2017) 23:775–81. 10.1038/nm.4324<?supplied-pmid 28436958?>28436958 </plain></SENT>
</text></ref><ref id="B289"><text><SENT sid="945" pm="."><plain>289.JeonOHDavidNCampisiJElisseeffJH. Senescent cells and osteoarthritis: a painful connection. J Clin Invest. (2018) 128:1229–37. 10.1172/JCI95147<?supplied-pmid 29608139?>29608139 </plain></SENT>
</text></ref><ref id="B290"><text><SENT sid="946" pm="."><plain>290.BussianTJAzizAMeyerCFSwensonBLvanDeursen JMBakerDJ. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature (2018) 562:578–82. 10.1038/s41586-018-0543-y<?supplied-pmid 30232451?>30232451 </plain></SENT>
</text></ref><ref id="B291"><text><SENT sid="947" pm="."><plain>291.BakerDJPetersenRC. Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest. </plain></SENT>
<SENT sid="948" pm="."><plain>(2018) 128:1208–16. 10.1172/JCI95145<?supplied-pmid 29457783?>29457783 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
